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Low neurotrophic support and a GABA deficit have been suggested as mechanisms underlying 
structural and functional abnormalities of the brain in depressed subjects. A parallel 
downregulation of brain-derived neurotrophic factor (BDNF) and GABA function-related genes 
including somatostatin (SST), a marker of GABA interneurons targeting the dendritic 
compartment of pyramidal cells, has been consistently observed during normal aging and in 
major depression. Here, translational research combining cell culture, animal and human 
postmortem studies has been conducted in search of a possible link between BDNF and GABA 
interneurons. 
I found that dendritic-targeting interneuron markers displayed a higher BDNF 
dependency compared to other GABAergic genes in BDNF-knockdown mice. To explore the 
nature and extent of the biological components linking BDNF and SST, we analyzed the top 200 
genes positively correlated with BDNF expression in the human brain and found that age-related 
BDNF reduction may induce synaptic alterations which are likely responsible for age-associated 
cognitive decline.  
Interestingly, SST and the α5 subunit of GABAA receptor (GABRA5), a subunit 
considered to be enriched in the post-synaptic compartment of SST (+) interneurons, are 
included in the top 200 genes, with GABRA5 displaying the highest correlation with BDNF 
expression among ~ 300,000 probes examined with the arrays. These data suggest that 
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the synaptic target of SST (+) interneurons, the distal dendrite, may act as a bridge between 
BDNF and SST. Therefore, we hypothesized that MDD is associated with reduced dendritic 
BDNF which results in low BDNF supply to SST (+) interneurons. Indeed, 3’ untranslated 
region (UTR)-containing-BDNF mRNA, which is known to migrate to the distal dendrites of 
pyramidal cells, showed downregulation in the dorsolateral prefrontal cortex (dlPFC) of 
depressed subjects and medial prefrontal cortex of stressed mice. Furthermore, such changes 
were closely linked to changes in dendritic-targeting interneuron markers. Knockdown of BDNF 
long 3’ UTR was sufficient to induce dendritic shrinkage, depressive-/anxiety-like behavior, and 
SST downregulation. Finally, pharmacological potentiation of TrkB prevented the development 
of depression-like behaviors following chronic stress in rodents. 
Together, I provide a mechanistic link between the GABA and neurotrophic hypotheses 
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1.0  INTRODUCTION 
1.1 MAJOR DEPRESSIVE DISORDER 
1.1.1 Overview: epidemiology, economic burden, diagnosis and treatment 
Major depressive disorder (MDD) is the most common psychiatric disease affecting 350 million 
people worldwide (WHO, 2012).  Lifetime prevalence of the disease is 17 % (Kessler et al., 
2005), 7 % of adults aged 18 or older reported that they had at least one major depressive 
episode in the past year (Substance Abuse and Mental Health Services Administration, 2013). 
MDD is one of the leading cause of disability (WHO, 2012), and costs the US more than 200 
billion dollars annually (Greenberg et al., 2015).  
To date, no reliable biomarkers have been discovered for the diagnosis and prognosis of 
MDD. MDD is diagnosed when a person experiences depressed mood or anhedonia, and five or 
more other symptoms including diminished ability to think or concentrate, feelings of 
worthlessness, recurrent thoughts of death, weight changes, sleep disturbance, or fatigue for at 
least 2 weeks (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, American 
Psychiatric Association, 2013). The majority of MDD patients also suffer from additional co-
morbid mental disorders such as anxiety (57%), substance abuse (30%) and personality disorder 
(44%) (Davis et al., 2008; Melartin et al., 2002).  
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Pharmacotherapy is usually offered as an initial treatment for mild-to-moderate MDD. 
Pharmaceutical action of common antidepressants, such as selective serotonin reuptake inhibitors 
(SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs), works through 
blocking membrane transporters, and therefore increasing monoamine level in the synaptic cleft. 
Although a large number of antidepressants are available in the market, significant problems 
remain to be solved. For example, these treatments may cause a wide range of side effects such 
as nausea, weight gain, sexual disability, fatigue, insomnia, dry mouth and blurred vision. 
Moreover, it takes several weeks before a significant improvement in symptoms is reached, and 
remission rates following 14 weeks of SSRI treatment are only 30 % (Trivedi et al., 2006).  
For patients with severe symptoms and/or resistance to antidepressant treatment, 
electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS) are recommended. 
Nonetheless, ECT causes memory loss in some patients, cannot be used for patients with 
unstable heart problems due to its effect raising heart rate and blood pressure (American 
Psychiatric Association, 2008). TMS is reported to produce fewer side effects; however, its 
effectiveness appears to be lower than that of ECT (Eranti et al., 2007; Padberg and George, 
2009). MDD is highly recurrent; at least 50% of patients who achieve remission from the first 
episode relapse in their lifetime and experience more severe symptoms and a longer duration of 
illness in recurrent episodes (Burcusa and Iacono, 2007; Ramana et al., 1995). 
The heterogeneous symptoms, high comorbidity with other diseases, low treatment 
efficacy and high relapse rate (Ferguson, 2001; Huynh and McIntyre, 2008; Trivedi et al., 2006) 
emphasize the need for an increased understanding of the pathophysiology of MDD and the 
development of better treatments. 
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1.1.2 Biological mechanisms of MDD 
Despite decades of intensive research, the biological mechanisms of MDD are far from clear. 
Failure of genome-wide association studies (GWAS) to identify genetic risk factors for major 
depression suggests that the disease results from the sum of multiple small factors rather than 
one single major deficit. However, there are several hypotheses that have been supported by 
repeated observations.  
1.1.2.1 Monoamine hypothesis 
The monoamine theory of MDD, which proposes that depression is caused by a monoamine 
deficit in the brain, was first introduced following the observation that drugs which deplete 
extracellular monoamine levels lead to depressive symptoms (Schildkraut, 1965) and further 
developed during investigations of the mechanism of antidepressant action.  
The early antidepressants were discovered by serendipity; isoniazid, a monoamine 
oxidase inhibitor (MAOI), and imipramine, a tricyclic antidepressant (TCA), were initially 
developed to treat tuberculosis and psychosis, but clinicians observed their anti-depressant effect 
in the treated patients. Both compounds increase brain concentrations of monoamines by 
inhibiting the enzyme breaking down monoamines (MAOI) and inhibiting reuptake of serotonin 
and noradrenaline as well as blocking diverse neurotransmitter receptors (TCA). Following the 
discovery that monoamines are taken up presynaptically (Axelrod et al., 1961; Thase et al., 1992), 
selective monoamine reuptake inhibitors were developed and still commonly used to treat MDD 
(reviewed in (Prins et al., 2011).  
The important role of optimal monoamine transmission on mood regulation is 
undeniable; however, the fact that current antidepressants need several weeks to months to show 
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therapeutic effects, despite immediate enhancement of monoamine neurotransmission after drug 
administration (Nestler et al., 2002), implies that additional mechanisms are involved and long-
term adaptations in the brain are essential. 
1.1.2.2 Neurotrophic hypothesis 
Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor widely expressed throughout 
the central nervous system including the hippocampal formation, cerebral cortex, thalamus, 
hypothalamus, amygdala, cerebellar granule cell layer and spinal cord (reviewed in (Edelmann et 
al., 2014)). It plays an important role in neurogenesis, differentiation, plasticity and survival. The 
BDNF gene has a complex structure, composed of at least 9 exons including 1 protein-coding 
and 8-10 non-coding exons (Figure 1) (Aid et al., 2007), as well as two polyadenylation sites 
(see Chapter 4 for more detailed information of splice variants). Each exon has its own promoter 
which regulates BDNF expression in response to various environmental factors such as stress 
(Rasmusson et al., 2002; Smith et al., 1995; Ueyama et al., 1997), enriched environments 
(Chourbaji et al., 2008; Rossi et al., 2006), diet (Molteni et al., 2002) and exercise (Cotman and 
Berchtold, 2002; Russo-Neustadt et al., 1999; Russo-Neustadt et al., 2001; Vaynman et al., 2004). 
These factors are also known to be associated with MDD.  
Decreased BDNF expression has been proposed as a mechanism underpinning structural 
changes of the brains of MDD subjects and stressed animals including cerebral atrophy, dendritic 
shrinkage, synaptic loss and impaired brain connectivity (Figure 2) (Drevets, 2000; Drevets et al., 
1998; Drevets et al., 1997; Kang et al., 2012; Rajkowska, 2000a; Rajkowska et al., 1999; 
Rajkowska et al., 2007; Stockmeier et al., 2004a; Videbech and Ravnkilde, 2004). This 
hypothesis is supported by limited, but direct evidence of low BDNF level in blood (Bocchio-
Chiavetto et al., 2010), and in postmortem tissue from the hippocampus (Dunham et al., 2009; 
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Thompson Ray et al., 2011) and amygdala (Guilloux et al., 2012) of MDD patients. Rodent 
studies provide further evidence that antidepressant treatments restore BDNF levels (Duman and 
Monteggia, 2006; Duman and Vaidya, 1998; Nibuya et al., 1996; Russo-Neustadt et al., 1999; 
Russo-Neustadt et al., 2001), that hippocampal infusion of BDNF produces antidepressant 
effects (Deltheil et al., 2008; Deltheil et al., 2009; Shirayama et al., 2002), and that blockade of 
BDNF signaling diminishes action of antidepressants (Shirayama et al., 2002).  
 
 
Figure 1. Structure of the human and rodent BDNF genes 
Exons are shown as boxes and the introns as lines. Numbers of the exons are indicated in roman numerals and the 
size of exons and introns are indicated in Arabic numerals. The 3′ coding exon (exon IX) contains two 
polyadenylation sites (poly A). The red boxes represent the translation start codon (ATG) and the green box shows 
protein coding region, including the rs6265 genetic variant implicated in the Val66Met polymorphism. Arrows 
indicate within-exon alternative splice sites (A, B, C, D). CpG islands were predicted with Methprimer software and 




Figure 2. Influence of stress on the morphology and proliferation of neurons and neurotrophic factor 
expression 
Immobilization stress decreases the complexity of pyramidal cell apical dendrites, and the number of spines in the 
prefrontal cortex (PFC). Stress also decreases neurogenesis and BDNF expression in the adult hippocampus (HP). 
From (Duman, 2009).  
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Recent discovery of a single-nucleotide polymorphism (SNP) in BDNF, Val66Met, in 
which Valine is substituted to Methionine at codon 66, has introduced interesting aspects to this 
hypothesis. Val66Met is a common polymorphism; allele frequency related to Met varies 18 to 
41 % of populations, depending on ethnicity (Shimizu et al., 2004). It has been found that the 
Met polymorphism is associated with disrupted subcellular translocation, activity-dependent 
secretion, neurogenesis and reduced dendritic complexity (Bath et al., 2012; Chen et al., 2006; 
Egan et al., 2003).  Consistent with these findings, human studies found cognitive impairment 
(Bath and Lee, 2006), defective fear extinction (Soliman et al., 2010), poor episodic memory, 
abnormal activity (Egan et al., 2003; Hariri et al., 2003) and reduced volume of the hippocampus 
(Bueller et al., 2006; Hajek et al., 2012; Molendijk et al., 2012), prefrontal cortex (Kim et al., 
2013; Pezawas et al., 2004), amygdala (Montag et al., 2009) in 66Met carriers.  
There are discrepancies between studies investigating the association between Val66Met 
polymorphism and depression. Nevertheless, given that the combination of genetic and 
environmental risk factors implicated in the etiology of MDD and the 66Met allele is related to 
the dysregulation of hypothalamic-pituitary-adrenal axis activity, disrupted BDNF function may 
increase stress susceptibility rather than directly contribute to the disease (Alexander et al., 2010; 
Dougherty et al., 2010; Shalev et al., 2009; Yu et al., 2012).   
Although there is controversy regarding whether BDNF deficiency is a cause or 
consequence of MDD, growing evidences indicates that BDNF deficiency and/or disrupted 
function is associated with many aspects of the disease, as well as stress susceptibility and the 
therapeutic effect of antidepressants. 
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1.1.2.3 GABA hypothesis 
Lastly, research has suggested that major depression is associated with an impaired excitation 
and inhibition balance, likely caused by GABA dysfunction. The GABA hypothesis of affective 
disorders was originally proposed by Emrich et al. based on the mood-stabilizing effect of 
sodium valproate, a GABAergic anticonvulsant (Emrich et al., 1980). Additionally, human 
studies reported decreased GABA concentrations in MDD patients in the occipital and frontal 
cortices, which were reversed after SSRI treatment or ECT (Gabbay et al., 2012; Hasler and 
Northoff, 2011; Hasler et al., 2007; Levinson et al., 2010; Sanacora et al., 2003; Sanacora et al., 
2002). Animal studies revealed a close linkage between diminished GABA transmission and 
behavioral deficits (Earnheart et al., 2007; Guidotti et al., 1985; Lloyd et al., 1983; Martin et al., 
1989; Petty and Sherman, 1980, 1981; Poncelet et al., 1987).  
GABA interneurons projecting to pyramidal neurons can be classified into two major 
groups based on their synaptic targets: (1) perisomatic- or (2) dendritic-targeting (Figure 3). Each 
interneuron population can be further subdivided by their molecular markers. Fast-spiking, 
perisomatic-targeting interneurons express parvalbumin (PV) and control spike timing of the 
output neurons (Ali and Thomson, 2008; Kawaguchi and Kubota, 1997; Muller et al., 2007). 
SST-expressing interneurons, including CORT- and NPY- positive populations, target the 
dendritic compartments of pyramidal cells and provide fine-tuning (Lin and Sibille, 2013). 
Consistent with reduced density of GABA interneurons in depressed brains (Guilloux et al., 
2012; Rajkowska et al., 2007), we observed depression-related downregulation of dendritic-
targeting interneuron markers in diverse corticolimbic areas including the dorsolateral prefrontal 
cortex, amygdala, and subgenual anterior cingulate cortex (sgACC) (Guilloux et al., 2012; Sibille 
et al., 2011; Tripp et al., 2011; Tripp et al., 2012). The markers of perisomatic-targeting 
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interneurons (CCK and PV) were relatively unaffected. Using a mouse model of depression, we 
showed that chronic stress produced a reduction in SST expression and most importantly, 
knockout of SST was sufficient to induce depressive-/anxiety-like phenotype in mice (Lin and 
Sibille, 2015). 
Studies have reported alterations in SST-positive dendritic-targeting GABA neurons 
across neurological disorders and normal aging, implying that these neurons might be highly 
susceptible to various biological challenges. While we found some clues that the selective 
changes in SST are related to low BDNF signaling (Guilloux et al., 2012; Tripp et al., 2012), 




Figure 3. GABA microcircuitry 
GABA neurons expressing somatostatin (SST), neuropeptide Y (NPY), and cortistatin (CORT) innervate and inhibit 
the distal dendrites of pyramidal neurons (PYR). Parvalbumin (PV) and cholecystokinin (CCK)-expressing 
interneurons target the cell body and axon initial segment, and vasoactive intestinal polypeptide (VIP)-expressing 
neurons target other GABA neurons. From (French et al., 2014). 
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1.1.3 UCMS: an animal model of MDD 
Although there are concerns about modeling a complex disease such as major depression in a 
rodent, it is undeniable that rodent models can provide great insights into the pathology of the 
disease. Models allow us to investigate molecular changes in the brain at a crucial time point and 
to examine the causality relationship between depression and various genetic and environmental 
factors. Furthermore, proper animal models are essential for the development and testing of 
novel therapeutic strategies for MDD.   
Unpredictable chronic mild stress (UCMS) is an animal model of depression commonly 
used in the field. The UCMS procedure consists of exposing rodents to a variety of randomized 
environmental and social stressors (e.g. light/dark cycle changes, predator scent, tilted cages, 
wet/no bedding, and cage mate changes) for several weeks. Publications report that animals 
exposed to this protocol show MDD-like physiological and behavioral changes such as fur 
degradation and weight loss, decreased intake of palatable food (interpreted as anhedonia-like 
behavior), decreased sexual behaviors, and changes in sleep patterns (reviewed in (Willner, 
2005)). Importantly, most of these behavioral changes can be reversed by chronic antidepressant 
treatment (Surget et al., 2008; Surget et al., 2009; Willner et al., 1992; Willner et al., 1987). 
1.1.4 Interaction of MDD and brain aging 
Age is one of the most potent risk factors for neurological disorders. Many neurodegenerative 
and psychiatric disorders have a typical range of age-of-onset: schizophrenia and bipolar disorder 
typically begin in early adulthood, autism is often first identified in toddlers, and Alzheimer’s 
and Parkinson’s disease are late-onset.  
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The effect of aging on clinical depression is controversial (Blazer, 1994; Glaesmer et al., 
2011; Kessler et al., 2010). The incidence of major depression in the community of individuals 
over the age of 65 is reported between 1% and 5% (Fiske et al., 2009), which is lower than that 
of young adults; however, studies using different rating scales demonstrate different results. The 
anhedonia-focused depression rating scale, Hospital Anxiety and Depression Scale (HADS-D), 
demonstrated a significant increase of incidence of depression in the community-dwelling 
elderly (Solhaug et al., 2012), and 15-30% of elderly individuals experience various depressive 
symptoms (Glaesmer et al., 2011; Koenig and Blazer, 1992; McKinney and Sibille, 2012). 
Overall, it is apparent that sub-threshold depression and depressive symptoms are more common 
in later life (Beekman et al., 1995). This may not be surprising given that the elderly population 
is more likely to experience negative life events such as age-related illnesses (Alzheimer's 
disease, Parkinson's disease, arthritis), social isolation because of death of a spouse and 
retirement, and cognitive or physical disability. Although 65- to 75-percent of late-life 
depression is treatable, elderly people sometimes accept depression as a normal part of aging.  
On the other hand, major depression is associated with an increased risk of developing 
cardiovascular diseases, dementia, diabetes and other diseases commonly observed in later life. 
This notion led to a hypothesis that MDD might accelerate aging (Verhoeven et al., 2014; 
Wolkowitz et al., 2010; Wolkowitz et al., 2011c). Interestingly, telomere length, considered a 
cellular marker of biological age, has been found shorter in MDD patients (Hartmann et al., 
2010; Hoen et al., 2011; Lung et al., 2007; Simon et al., 2006; Verhoeven et al., 2014; Wikgren 
et al., 2012; Wolkowitz et al., 2011a). 
Accumulating evidence suggests the potential interactive effects of stress and aging on 
the vulnerable neuronal population (Figure 4). Mood symptoms often precede the onset of 
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neurodegenerative disorders (Jost and Grossberg, 1996; Tolosa et al., 2007). Similar to MDD, 
decreased brain volume, synaptic loss, and functional impairment of corticolimbic areas, 
including the dlPFC, have been observed in older subjects who do not show obvious 
neurological disease symptoms (Arnsten, 2009b; Bloss et al., 2011; Cook and Wellman, 2004; 
Holmes and Wellman, 2009; McEwen and Gianaros, 2011; Morrison and Baxter, 2012; Radley 
et al., 2004; Wang et al., 2011). Human postmortem studies from our group found a profound 
overlap between normal aging- and depression-related gene expression changes (Douillard-
Guilloux et al., 2013; Erraji-Benchekroun et al., 2005; Glorioso et al., 2011; Glorioso and Sibille, 
2011) including downregulation of SST and BDNF. Animal studies reported that both stress and 
aging impair the same class of spines, i.e., thin, highly plastic spines (Bloss et al., 2010; Bloss et 
al., 2011; Dumitriu et al., 2010). Interestingly, it seems that the effect of stress on molecular, 
anatomical and functional changes is augmented in older animals (Juster et al., 2010; Lupien et 
al., 2009; McEwen and Morrison, 2013). Aged animals display higher basal and post-stress 
corticosterone levels compared to young animals (Issa et al., 1990), and fail to restore dendritic 
complexity in the absence of stress (Bloss et al., 2010), thus indicating a loss of cellular 
resilience. Together, these results suggest that the emotion regulatory system may be selectively 
affected by early homeostatic changes during normal aging (further review is available in 
Appendix A). Understanding the underlying mechanisms in addition to the possible moderators 
and effectors of normal brain aging will provide important insights into pathological declines in 
brain function with age.  
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Figure 4. A proposed model of age-by-disease interaction 
Reduction of disease-related genes below threshold (horizontal red line) marks the onset of symptoms. Changes in 
the trajectory of age-related changes of disease-related genes (Y-axis) determine at what age (X-axis), or if, an 
individual may develop symptoms (vertical red arrows). Modulators (blue arrows) may thus place individuals on ‘‘at 
risk’’ or ‘‘protected’’ trajectories. From (Glorioso and Sibille, 2011), originally from (Glorioso et al., 2011). 
1.2 AIMS OF THIS DISSERTATION 
Impaired structural and functional connectivity, GABA deficits, and selective downregulation of 
dendritic-targeting interneuron markers have been repeatedly observed in major depression. The 
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aim of this dissertation is to identify a mechanistic link between these different phenomena by 
focusing on the well-known neurotrophic factor BDNF. As a starting point, I determined the 
degree of BDNF dependency of GABA-related genes in the cingulate cortex of transgenic mice 
with low BDNF expression, and compared the findings with human postmortem MDD brains 
(Chapter 2). In order to (1) find a possible link between BDNF and SST and (2) assess how 
normal age-related BDNF changes contribute to transcriptome remodeling - which may provide 
an important insight into the early stage of pathological declines in brain function - I identified 
genes potentially regulated by BDNF in the prefrontal cortex of control subjects and directly 
addressed the causality question via temporal inhibition of BDNF/TrkB signaling (Chapter 3). 
Finally, I investigated a mechanism underlying high BDNF dependency of SST (+) dendritic-
targeting interneurons and tested the antidepressant effect of a TrkB agonist, 7,8-
dihydroxyflavone (Chapter 4).  
 All of my research efforts across correlative (human) and causative (cell and mouse) 
studies have provided (i) evidence for the interactive influence of aging and stress on depression, 
(ii) the biological mechanism underlying the high vulnerability of dendritic-targeting 
interneurons that is widely observed in stress- and aging-related neurological disorders, and (iii) 
targets for the development of preventive interventions. 
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2.1 INTRODUCTION 
Major depressive disorder is a debilitating disorder of low affect and altered mood regulation that 
affects approximately 17% of the population at some point in life, resulting in serious personal, 
social, and economic burdens (Kessler et al., 2003). The prevalence of major depressive disorder 
is two times higher in women than in men. Female patients with the disorder tend to have higher 
symptom numbers, a more severe type of depression, and greater risk of recurring episodes 
compared with male patients, but the underlying biological vulnerabilities have not been 
characterized (Perugi et al., 1990). Changes in the structure, function, and coordinated activity of 
several brain regions may underlie impaired mood regulation in depression (Seminowicz et al., 
2004). Increased metabolic activity in one of these regions, the subgenual anterior cingulate 
cortex, has been consistently reported in the induction of the depressive state, and subgenual 
anterior cingulate cortex metabolism is reversed by pharmacological treatment (Mayberg et al., 
2000) and deep brain stimulation (Mayberg et al., 2005). 
Low neurotrophic support in limbic brain regions has been proposed as a unifying 
hypothesis for the reduced density or cell numbers in the frontal cortex (Rajkowska et al., 2001) 
and amygdala (Bowley et al., 2002) and the reduced hippocampal volume observed in 
individuals with major depression (Videbech and Ravnkilde, 2004). Rodent studies have 
demonstrated that various antidepressant treatments increase brain-derived neurotrophic factor 
(BDNF) expression (Schmidt and Duman, 2007), and BDNF infusion into the hippocampus is 
sufficient to produce an antidepressant-like effect (Shirayama et al., 2002). Despite abundant 
animal studies supporting the close relationship between BDNF and depression, direct evidence 
in humans is limited to reports of low circulating peripheral BDNF levels, which are normalized 
by antidepressant treatment (Molendijk et al., 2011), and studies demonstrating reduced pro-
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BDNF and BDNF levels in the postmortem amygdala of depressed female subjects (Guilloux et 
al., 2012) and in the hippocampal tissue in depressed patients (Dunham et al., 2009; Thompson 
Ray et al., 2011). Additionally, studies have reported that individuals who die by suicide exhibit 
low hippocampal and midbrain BDNF levels (Dwivedi et al., 2003), reduced activity-dependent 
BDNF expression by hypermethylation of promoter/exon IV of the BDNF gene (Keller et al., 
2010), and, in carriers of the BDNF Met allele, increased risk for violent suicide (Perroud et al., 
2008; Pregelj et al., 2011), together providing additional evidence that BDNF has a role in the 
psychopathology of major depression. 
In parallel, human imaging and basic science studies have suggested excitation/inhibition 
impairment in individuals with major depression that is potentially mediated by decreased 
GABA content (Luscher et al., 2011). We recently reported down-regulation of several GABA-
related genes in the dorsolateral prefrontal cortex (Sibille et al., 2011), subgenual anterior 
cingulate cortex (Tripp et al., 2011), and amygdala (Guilloux et al., 2012) in patients with major 
depression, potentially affecting somatostatin-positive dendritic targeting interneurons. We 
further demonstrated that a set of amygdala-related gene changes (affecting the TAC1, CORT, 
NPY, SST, RGS4, and SNAP25 genes [Table 1]) correlate with reduced BDNF expression in 
depressed patients and in mice with reduced BDNF function, hence identifying a pattern of 
reduced BDNF-dependent gene expression in major depression (Guilloux et al., 2012) and 
providing supporting evidence for a link between the neurotrophic (Schmidt and Duman, 2007) 
and GABA (Luscher et al., 2011) hypotheses implicated in depression. 
 In the present study, we investigated molecular evidence for a low BDNF and reduced 
GABA function pathway in the subgenual anterior cingulate cortex in individuals with major 
depressive disorder. We first tested the degree of BDNF dependency on gene expression of a set 
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of GABA- and BDNF-related genes in the cingulate cortex of mice with reduced BDNF function. 
Our choice of genes was determined by our previous study of the amygdala in depressed 
postmortem subjects (Guilloux et al., 2012) to enable comparative analyses across the two 
studies. Based on this information, we assessed changes in three sets of genes, with high, 
intermediate, or no BDNF dependency, in human subgenual anterior cingulate cortex using 
postmortem brain samples from a large cohort of subjects with major depressive disorder and 
matched comparison subjects. Exploratory analyses were performed on putative sex differences 
in expression patterns, given the greater female vulnerability and the previous findings of more 
robust somatostatin down-regulation in women with major depression (Tripp et al., 2011). 
2.2 MATERIALS AND METHODS 
2.2.1 Human postmortem subjects  
After consent from the next of kin, brain samples were obtained during autopsies performed at 
the Allegheny County Medical Examiner’s Office (Pittsburgh) using procedures approved by the 
University of Pittsburgh Institutional Review Board and the Committee for Oversight of 
Research Involving the Dead. Consensus DSM-IV diagnoses were made by an independent 
committee of experienced clinical research scientists using information from clinical records, 
toxicology results, and standardized psychological autopsies (Glantz et al., 2000). Fifty-one pairs 
of subjects were analyzed. Each pair consisted of one subject with major depressive disorder and 
a comparison subject matched for sex; group means for age, postmortem interval, and brain pH 
were nearly identical (see Table 5 in the Appendix B). Subgenual anterior cingulate cortex 
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samples containing all six cortical layers were harvested from coronal sections as described 
elsewhere (Sibille et al., 2009b). 
2.2.2 Mice 
BDNF-heterozygous (Bdnf+/−) mice (3–4 months old) were bred on a mixed S129/Sv×C57BL/6 
genetic background (Korte et al., 1995). BDNF exon-IV knockout (BdnfKIV) mice were crossed 
on C57BL/6 as described elsewhere (Sakata et al., 2009). All mice were maintained under 
standard conditions (i.e., in a 12/12-hour light-dark cycle, in 22°C [SD=1], and with food and 
water ad libitum). Brains were rapidly removed and flash frozen on dry ice. The left and right 
cingulate cortices were micropunctured using 0.5-mm diameter punches (Sibille et al., 2009b) 
and stored in TRIzol (Invitrogen, Carlsbad, Calif.) at –80°C. All animal care and treatment was 
in accordance with the Guide for Care and Use of Laboratory Animals established by the 
National Institutes of Health. 
2.2.3 Real-time quantitative polymerase chain reaction (PCR) 
Total RNA was isolated from TRIzol homogenates of the subgenual anterior cingulate cortex in 
all 51 pairs of postmortem subjects (major depression and comparison subjects) and of the 
cingulate cortex in rodents. The samples were purified using RNeasy spin columns (Valencia, 
Calif.), and RNA integrity was assessed using the Agilent 2100 Bioanalyzer (Agilent 
Technologies, Walbronn, Germany). To generate cDNA, 1 μg total RNA was mixed with oligo-
dT primers and SuperScript II reverse transcriptase (Invitrogen, Carlsbad, Calif.) per the 
manufacturer’s protocol. PCR products were amplified in quadruplets on a Mastercycler real-
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time PCR machine (Eppendorf, Hamburg, Germany) using universal PCR conditions as 
described elsewhere (Tripp et al., 2011). Results were calculated as the geometric mean of 
threshold cycles normalized to three validated internal controls (actin, glyceraldehyde-3-
phosphate dehydrogenase, and cyclophilin G). 
2.2.4 Gene selection 
We assessed mRNA expression of several genes that we previously demonstrated to be affected 
in the amygdala in individuals with major depression and that display various levels of BDNF 
dependency, based on expression levels in the amygdala in the same strains of mice with reduced 
BDNF functions (Bdnf+/− and BdnfKIV) used in the present study (Korte et al., 1995; Sakata et al., 
2009). Our set includes genes related to BDNF signaling (BDNF and TRKB), BDNF-dependent 
genes (CORT, NPY, SST, VGF, TAC1, SNAP25, and RGS4), and GABA-associated genes 
(GAD1, GAD2, GABRA1, SLC6A1, CALB2, PVALB, SST, NPY, and CORT) (Table 1). 
2.2.5 Protein isolation and BDNF quantification 
Following RNA extraction, acetone precipitation of proteins was carried out from the TRIzol 
samples, and Western blot analysis was performed as described elsewhere (Sibille et al., 2009b). 
Dual signals were detected using the Odyssey Infrared Imaging System (LI-COR Biosciences, 
Lincoln, Neb.), and BDNF signal ratios to actin were calculated. Samples were processed in 
matched pairs on the same gel, and results were replicated for a total of three different Western 
blots. Test assays were run with 5–50 μg of total protein using the following antibodies: mouse 
antihuman BDNF (R&D Systems, Minneapolis), antihuman TrkB (sc-8316; Santa Cruz 
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Biotechnology, Santa Cruz, Calif.), and antiactin (A2228; Sigma-Aldrich, St. Louis). We also 
measured BDNF using an enzyme-linked immunosorbent assay (ELISA) kit (Promega, Madison, 
Wisc.). 
2.2.6 Statistical analysis 
Differences in diagnosis-dependent gene expression were determined by analysis of covariance 
(ANCOVA) using SPSS (SPSS, Chicago). To determine which covariates to include in the gene-
specific models, each nominal factor was tested as the main factor using analysis of variance 
(ANOVA), scale covariates were tested using Pearson’s correlation, and repeated measures were 
corrected using the modified Holm-Bonferroni method (see Table 6 in the Appendix B). Samples 
were analyzed for the presence of antidepressant medication at the time of death. Given the small 
number of observations (N=9), benzodiazepines were not formally analyzed. No other 
psychotropic medications were present at the time of death. ANCOVA models, including 
significant cofactors, were then applied to the combined and sex-specific analyses. For the rodent 
analyses, ANOVA models with sex as a cofactor were applied to the combined analysis, and 
unpaired two-tailed t tests were performed in the separate male and female analyses. Values were 
then adjusted across genes for multiple testing using a second modified Holm-Bonferroni test 




2.3.1 BDNF-dependent gene expression in the cingulate cortex in mice with altered BDNF 
function  
Since BDNF expression and function vary significantly depending on brain regions, sex, and 
cellular activity, we first tested the role of BDNF in regulating the expression of the genes of 
interest in the cingulate cortex of mice that were heterozygous for a constitutive deletion of the 
Bdnf gene (Bdnf+/−) or that had a targeted disruption of exon IV (BdnfKIV), with the latter 
mutation resulting in blockade of activity-dependent BDNF protein expression (Sakata et al., 
2009). Bdnf mRNA levels were reduced in Bdnf+/− mice (Table 1). When the groups were 
separated by sex, this decrease reached statistical significance only in male mice, potentially 
reflecting reduced analytical power in smaller groups. Bdnf mRNA levels were also reduced in 
BdnfKIV mice, in both the combined and sex-specific groups (Table 1). These latter results reveal 
that constitutive and activity-dependent functions of BDNF are not only reduced in the cingulate 
cortex in BdnfKIV mice, which is consistent with an independent study of the same BdnfKIV 
mouse strain reporting activity-dependent BdnfKIV promoter-driven transcription abolishment in 
the cortex (Martinowich et al., 2011), but they are also significantly reduced in basal 
transcription by promoters I, II, III, VI, and IXa. The levels of Trkb, the main receptor of Bdnf, 
were not affected in the two mouse models. 
Using the Bdnf+/− and BdnfKIV mouse models, we next investigated the degree of BDNF 
regulation on target genes (defined as BDNF dependency) within the cingulate cortex. The 
quantitative PCR (qPCR) analysis revealed robust and significant decreases in gene transcript 
levels for Cort, Vgf, Sst, Tac1, and Npy expression (false discovery rate-corrected significance 
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in the combined male-female group in at least one strain of mice) but less robust effects on 
Snap25 and Gad2 expression (uncorrected significance in the combined male-female group in at 
least one strain of mice) and little or no effect of decreased BDNF function on Gad1, Pvalb, 
Rgs4, Gat1, and Gabra1 expression (no difference in the combined male-female group and 
uncorrected significance in the separate sex groups in one strain of mice or no change observed 
at all). Combined, these findings provided us with three sets of genes with a gradient of BDNF 
dependency in the cingulate cortex. Results of this analysis are summarized in Table 1. 
Table 1. Assessment of Brain-derived neurotrophic factor (BDNF) dependency on target gene expression in 




2.3.2 BDNF-dependent gene expression changes in the subgenual anterior cingulate 
cortex in postmortem subjects with depression 
To evaluate subgenual anterior cingulate cortex BDNF function in the postmortem brain of 
subjects with major depression and comparison subjects, we used qPCR to measure the mRNA 
expression levels of BDNF, of the BDNF receptor TRKB, and of the three sets of genes with 
variable BDNF dependency described above. The qPCR measures were first evaluated for the 
effect of relevant cofactors to include in the main ANCOVA models for each gene, as described 
earlier. None of the investigated cofactors displayed consistent effect. The cofactor analyses and 
ANCOVA inclusions are summarized in Table 6 in the Appendix B. 
Results from the ANCOVA analyses for the effects of major depression are summarized 
in Table 2. Although BDNF mRNA levels were not changed, mRNA levels of the BDNF 
receptor TRKB were significantly reduced by approximately 30% after correction for multiple 
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testing. In view of the negative BDNF mRNA finding and the complex regulation of BDNF 
mRNA at the protein level, we attempted to measure extracts using quantitative Western blot 
tests and ELISA. However, the pro- and mature forms of BDNF were below detection levels in 
the subgenual anterior cingulate cortex samples using both approaches. Similarly, the signal-to-
background ratio for TrkB protein levels was low in the samples and precluded robust 
quantification. 
Reduced expression was identified for CORT (–33%), SNAP25 (–38%), VGF (–35%), 
SST (–34%), NPY (–37%), GAD1 (–25%), GAD2 (–28%), and PVALB (–33%). Reduced 
expression was also observed for TAC1 (–25%) but only at nominal uncorrected significance. 
The RGS4, GABA transporter 1/SLC6A1, calretinin/CALB2, and GABRA1 genes were 
unchanged. 
When the groups were segregated by sex, BDNF levels remained unchanged, and TRKB 
was similarly reduced in both male (–29%) and female (–32%) depressed subjects compared 
with the respective comparison subjects, although results were less robust and only showed 
nominal uncorrected significance. Overall, male depressed subjects exhibited more robust 
decreased expression across the gene panels than female depressed subjects compared with the 
respective comparison subjects. Out of the eight genes displaying false discovery rate-corrected 
significance in the combined male-female group, six remained significant at false discovery rate-
corrected p values and two at uncorrected values in the male cohort, compared with two and 
three genes, respectively, in the same categories in the female cohort. Out of the four genes 
showing no effect in the combined group, calretinin/CALB2 was decreased in the male cohort at 
false discovery rate-corrected significance. 
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When summarized by BDNF-dependent categories (Table 2), these results suggest a 
robust decrease in BDNF signaling in the subgenual anterior cingulate cortex in depressed 
subjects, with changes related to GABA functions also including genes with moderate or low 
BDNF dependency. 
Table 2. Alterations in proximal Brain-derived neurotrophic factor (BDNF) signaling machinery and distal 
BDNF-dependent genes in the subgenual anterior cingulate cortex of postmortem subjects with major 
depressive disorder 
 
2.3.3 BDNF-dependent mRNA sex differences in comparison postmortem subjects 
To investigate potential sources of the discrepancy in altered major depression-related gene 
expression between male and female subjects, we compared expression differences between 
male and female comparison subjects (i.e., individuals without psychiatric diagnoses). We found 
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no sex differences in BDNF or TRKB mRNA expression, but several genes within the 
investigated panel, including CORT, NPY, CALB2, and TAC1, showed reduced baseline 
expression in women (Figure 5). This suggests that levels of expression in the female 
comparison subjects may already be closer to the low expression levels observed in depressed 
subjects. 
 
Figure 5. Significant sex differences in gene expression in postmortem comparison subjectsa 
a Comparisons are between male and female comparison subjects without psychiatric diagnoses. SST mRNA 
expression was lower in female subjects at a level that fell short of significance (p<0.1). Black bars indicate mean 
values, and red bars indicate the coefficients of variation. The asterisk indicates statistical significance (p<0.05). 
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2.4 DISCUSSION 
Seeking molecular evidence in support of a low BDNF and reduced GABA function pathway in 
the subgenual anterior cingulate cortex in individuals with major depression, we first relied on 
two strains of mice with reduced BDNF function to determine the extent to which our genes of 
interest depend on BDNF for expression in the cingulate cortex (Table 1). Translating this 
information to human subjects with major depression and measuring expression levels in their 
subgenual anterior cingulate cortex, we observed no changes in BDNF itself, reduced expression 
of TRKB, the main receptor through which BDNF signals, and reduced mRNA levels of several 
genes for which expression depends on BDNF (Table 2). Among these BDNF-dependent and 
depression-affected genes, the reduced expression of several markers of GABA-ergic 
interneurons that specifically target the dendritic compartment of pyramidal neurons (SST, NPY, 
and CORT) suggests the presence of a reduced dendritic inhibition phenotype in individuals with 
major depression, downstream from low BDNF signaling. GABA-related changes also extended 
to genes with modest or no evidence for BDNF dependency (based on mouse studies [also see 
Table 1 and Table 2]), suggesting that additional factors lead to reduced GABA function in 
depression. Overall, results were more robust in men, which is contrary to our previous 
observations in the amygdala, in which depressed women exhibited reduced BDNF levels (but 
not TRKB levels) and greater BDNF-dependent gene changes compared with men. Together, 
these results suggest a core BDNF-/GABA-related pathology in major depression that affects 
markers of interneurons targeting pyramidal cell dendrites and that displays sex- and brain 
region-specific features. 
With the exception of sex and, to a lesser extent, age, none of the clinical, demographic, 
and technical parameters had any consistent detectable effects on gene expression in our 
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relatively large cohort of human subjects. Death by suicide has been associated with reduced 
BDNF expression, but differences observed in the present study appeared to be more robust in 
subjects who did not die by suicide, compared with the respective comparison subjects (see 
Table 7 in Appendix B). 
When the groups were segregated by sex, we observed similar changes in TRKB 
expression and overall lower statistical significance of changes in depression-related gene down-
regulation in female subjects, although not systematically (Table 2). Notably, the expression 
levels of three BDNF-dependent genes (CORT, NPY, and TAC1) were already lower in female 
comparison subjects relative to male comparison subjects (Figure 5). Despite lower baseline 
levels, expression changes for CORT, TAC1, and NPY still displayed greater or equal statistical 
significance and effect size in depressed female subjects compared with depressed male subjects. 
Thus, despite a less robust profile of molecular changes, the low female baseline expression for 
some genes may result in a greater propensity to reach the threshold of low pathophysiological 
function (Table 2). Finally, the overall male-female similarities in gene changes downstream 
from low BDNF in the two mouse strains (Table 1) and the reduction or absence of changes in 
human female subjects for genes with intermediate and low BDNF dependency (SNAP25, 
GAD1/GAD2 [Table 2]) suggest the presence of additional sex-specific moderating factors in 
human subjects. This is consistent with our previous study of the amygdala in depressed male 
(Sibille et al., 2009b) and female (Guilloux et al., 2012) subjects, in which BDNF and BDNF-
dependent genes were robustly affected in women but not in men. Together, these results support 
the concept that sex differences in the vulnerability to and the expression of major depression 
may not result from different pathophysiological mechanisms but rather from moderating 
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biological factors acting on a core phenotype implicating a putative reduction in GABA function 
and dendritic targeting interneuron vulnerability. 
SST, NPY, and CORT are three neuropeptide coding genes with overlapping patterns of 
expression in mice that are found in approximately 20% of interneurons and that have the 
functional characteristic of providing GABA-mediated inhibition to distal dendrites of pyramidal 
neurons. Moreover, TAC1, the fourth neuropeptide coding gene that is similarly down-regulated 
in the subgenual anterior cingulate cortex and amygdala in individuals with major depression 
(Figure 6), encodes for substance P, a gene product with putative antidepressant activity (Ratti et 
al., 2011), which in the cortex mainly activates SST-positive cells through NK1R receptor 
binding (Vruwink et al., 2001). Since all four genes are dependent on BDNF for their expression 
(Table 1), low BDNF signaling may orchestrate a synergy between decreased TAC1, SST, NPY, 
and CORT expression, leading to reduced inhibition onto the dendritic trees of targeted 
pyramidal neurons. VGF and SNAP25, two genes involved in synaptic function and previously 
implicated in major mental illnesses, were also found to be BDNF dependent and down-
regulated in the subgenual anterior cingulate cortex in subjects with major depression, suggesting 
that a broader BDNF-dependent module may be affected. Finally, expression of GAD1, a gene 
encoding an enzyme that produces GABA, and expression of PV, a gene encoding a marker for 
fast spiking GABA interneurons targeting the cell body and axon initial segment, were also 
down-regulated. For PV and GAD1, the mechanism appears to be independent of reduced BDNF 
function (Table 1, Table 2). Notably, PV levels were not affected in other brain regions (the 
dorsolateral prefrontal cortex [e.g., Sibille et al. 2011] and the amygdala [e.g., Guilloux et al. 
2012]), and calretinin (CALB2), a marker for a third interneuron subset, displayed reduced 
baseline expression and no depression-related changes in the subgenual anterior cingulate cortex 
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but was decreased in the amygdala in depressed female subjects (Figure 6). Together, these 
findings put forward critical observations of the pathology of major depression, which may relate 
to three consecutive biological scales: 1) molecular function, manifested by altered BDNF-
/TrkB- and GABA-associated gene function; 2) cellular microcircuitry, in which findings appear 
to be clustered by function (i.e., dendritic inhibition); and 3) circuit moderators, in which sex-
related factors and brain regions are relevant modulators to gene expression in major depression. 
Hence, reduced GABA-mediated inhibition of incoming information in pyramidal dendrites may 
represent a putative microcircuitry-level phenotype underlying the increased activation of the 
subgenual anterior cingulate cortex and amygdala that is frequently reported in studies of 
patients with major depression (Mayberg et al., 1999; Siegle et al., 2007). In turn, restoring 
dendritic inhibitory function may reduce pyramidal cell activation and excitatory tone and 
contribute to the reduction in activation of the subgenual anterior cingulate cortex with positive 
treatment response to therapeutic intervention (e.g., deep brain stimulation, antidepressants) 
(Mayberg et al., 2000; Mayberg et al., 2005). 
Some of the limitations of these results are inherent to investigation of heterogeneous 
cohorts and of postmortem brain samples. Large numbers of clinical, demographic, and technical 
parameters have to be taken into consideration, and results are mostly correlative and cannot 
provide insight into developmental processes in major depression. Our relatively large cohort 
size allowed us to rule out major effects of putative confounds (details are summarized in Table 
6 in Appendix B), but the results will need to be confirmed in independent cohorts. 
The causal link between reduced BDNF signaling and altered gene expression was 
inferred from analyses of rodents with genetically induced reduction in BDNF function, but 
species differences may exist, and thus the different labels of gene-specific BDNF dependency 
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may vary. The fact that regional variations in BDNF dependency were also observed in rodents 
suggests that aspects of the human gene regulation patterns are conserved across species. This 
latter observation supports the need for further studies of rodent models with more refined 
genetic manipulations affecting specific interneuron populations, for instance, to assess the effect 
on reduced dendritic inhibition on the local microcircuitry in the amygdala and cingulate cortex 
and downstream behavioral phenotypes. Indeed, it is evident that the complexity of the putative 
BDNF-mediated cellular and signaling phenotype observed in human major depression is not 
fully replicated in currently available genetic rodent models, and thus caution should be applied 
when interpreting rodent behavioral outputs downstream from broad genetic changes; for 
instance, Bdnf+/− and BdnfKIV mice exhibit normal and increased emotionality, respectively 
(Ibarguen-Vargas et al., 2009; Sakata et al., 2010). Disruption of forebrain-specific BDNF leads 
to higher emotionality when combined with exposure to chronic stress in female mice (Autry et 
al., 2009; Monteggia et al., 2007). Conversely, low ventral striatum BDNF can have 
antidepressant-like effects (Berton et al., 2006). Our observation in humans of reduced 
expression of BDNF in the amygdala and of reduced TRKB in the subgenual anterior cingulate 
cortex suggests that altered BDNF signaling may represent a complex integration of currently 
unidentified upstream events (e.g., stress factors, developmental trajectories, and genetic 
variation), which result in similar core downstream changes (i.e., reduced markers of dendritic 
inhibition) and that are further moderated by numerous factors (e.g., sex, brain region, and brain 
activity). 
Finally, it is also becoming evident that the observed findings are not specific to major 
depression, since similar reductions in BDNF and SST expression have been reported in studies 
of other neuropsychiatric (e.g., schizophrenia (Hashimoto et al., 2005b; Mellios et al., 2009) and 
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bipolar disorder (Fernandes et al., 2011)) and neurological (e.g., Alzheimer’s disease and 
Huntington’s disease) disorders. Thus, our findings may more accurately reflect a molecular and 
cellular endophenotype that implicates BDNF signaling and GABA microcircuitry and that has 
its own etiological factors. However, the restricted scope on markers affecting dendritic 
inhibition that we observed differs from observations in studies of other diseases in which 
changes occur in the context of other core pathologies, such as robust PV-related GABA 
dysfunction in schizophrenia (Hashimoto et al., 2008) or neurodegenerative processes in 
Alzheimer’s disease (Podtelezhnikov et al., 2011). Investigating the etiological factors and 
phenotypic outputs of these respective molecular and cellular endophenotypes outside the 
restriction of the categorical definitions of psychiatric and neurological illnesses may provide 
dimensional insight into relevant proximal pathophysiological mechanisms to be targeted for 
therapeutic purposes, while their patterns of co-occurrences may be informative of mechanisms 
underlying clusters of symptoms that are enriched in clinically defined disorders. 
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Figure 6. BDNF/TRKB and associated GABA marker dysregulation in the subgenual anterior cingulate 
cortex and amygdala in postmortem subjects with major depressive disordera 
a Reduced BDNF signaling in major depressive disorder is suggested by the findings of low BDNF in the amygdala 
and low TrkB in the subgenual anterior cingulate cortex. Analyses of mice with reduced BDNF functions suggest 
that co-occurring GABA-related gene changes are partly downstream from low BDNF signaling, but the exact 
nature and extent of downstream gene changes are moderated by brain region- and sex-specific factors. Comparison 
findings in the amygdala are taken from a previous study (12). SgACC=Subgenual anterior cingulate cortex. 
 36 
3.0  PAPER 2: THE ROLE OF BDNF IN AGE-DEPENDENT CHANGES OF 
SYNAPTIC MARKERS IN HUMAN PREFRONTAL CORTEX 
Hyunjung Oh1, David A. Lewis1, Etienne Sibille1,2§ 
 
1Department of Psychiatry, Center for Neuroscience, University of Pittsburgh, PA, USA 
2Campbell Family Mental Health Research Institute of CAMH; Departments of Psychiatry, and 
Pharmacology and Toxicology, University of Toronto, Toronto, Canada 











This work is submitted to Biological Psychiatry. 
 37 
3.1 INTRODUCTION 
With dramatic growth of the older population, the need to understand the mechanism and 
consequence of aging on the brain has become critically important. The effect of aging on the 
incidence of psychiatric disease remains controversial (Blazer, 1994; Glaesmer et al., 2011; 
Kessler et al., 2010). While sub-threshold depression and depressive symptoms are more 
common in later life (Beekman et al., 1995), they are often misattributed to aging per se, leading 
to under-diagnosis of depression. Animal studies show that the effects of stress on cognitive, 
neuroendocrine, biochemical and anatomical changes are augmented in older subjects (Juster et 
al., 2010; Lupien et al., 2009). 
Recent advances in understanding the molecular and cellular bases of altered mood 
regulation in adult depressed subjects, and the observation of a considerable overlap between 
normal aging and depression-related brain changes (McKinney et al., 2012; McKinney and 
Sibille, 2013), suggest that aspects of mood regulatory mechanisms may be selectively 
vulnerable to early homeostatic changes during normal aging. Indeed, older age is a potent risk 
factor for the functional decline of the prefrontal cortex (PFC), which is important for cognitive 
function, working memory, and emotion regulation in all species, ranging from rodents to 
humans. Imaging studies report smaller PFC volume in elderly subjects without obvious 
neurological disease (Tisserand et al., 2002). Consistent with functional impairment and brain 
atrophy, a decrease in neuronal body size, dendritic length, and loss of synapses without loss of 
neurons have been observed in postmortem studies (Morrison and Baxter, 2012; Rajkowska, 
2000b; Stockmeier et al., 2004b). 
BDNF, a small secreted protein, and its receptor, TrkB, play important roles in neuronal 
development, differentiation, maintenance and plasticity throughout life. In the brain, two 
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isoforms of TrkB are abundantly expressed: full-length (TrkB-FL) and truncated form (TrkB-T1). 
In contrast to TrkB-FL which binds to BDNF and activates downstream kinase cascades, TrkB-
T1 lacks intracellular catalytic domain and therefore act as an endogenous inhibitor of TrkB-FL 
by competing for the available BDNF pool (Eide et al., 1996; Gupta et al., 2013). Low BDNF 
and/or TrkB expression has been reported in multiple brain disorders and normal brain aging 
which are often accompanied by mild brain atrophy, reduced neuronal function, and synaptic 
loss (Durany et al., 2001; Guilloux et al., 2012; Hattiangady et al., 2005; Howells et al., 2000; 
Phillips et al., 1991; Romanczyk et al., 2002; Thompson Ray et al., 2011). Brain-specific 
deletion of BDNF or TrkB in mouse induces neuronal shrinkage, dendritic retraction in the 
cortex, and cognitive and learning deficit (Gorski et al., 2003a; Gorski et al., 2003b; Xu et al., 
2000). These data imply that normal aging-associated BDNF and TrkB changes in the PFC 
might compromise synaptic integrity and function, although this link has not been tested in 
humans. 
The biological role of BDNF has been thoroughly studied, however, investigating BDNF-
driven changes in vivo and/or in human subjects is challenging due to its low endogenous level, 
and complex regulation by multiple promoters. Most studies were conducted with in vitro 
models, sometimes with the aid of overexpression or exogenous application of BDNF. Moreover, 
whereas changes in BDNF levels seem an obvious candidate biological event for age-related 
structural and functional changes, numerous other age-related complex processes occur, 
including among others, increased inflammation, reduced blood flow, accumulated free radical 
damage to macromolecules; all potentially contributing to the molecular, structural and 
functional alterations of the brain.  
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In the present study, we investigated age-related BDNF change in the human prefrontal 
cortex and specifically focused on its putative contribution to altered transcriptome profile 
occurring during normal aging. We then used a conditional genetic mouse model to directly test 
the putative causal role of BDNF/TrkB signaling in altered aging-associated expression patterns. 
We predicted that reduced BDNF directly contribute to reduced synaptic function through altered 
expression of markers for inhibitory and excitatory neurons and synaptic genes. 
3.2 MATERIALS AND METHODS 
3.2.1 Human postmortem subjects  
Postmortem brains were collected from the Allegheny County Coroner’s Office (Pittsburgh, PA) 
after consent from next of kin. The neuropsychiatric-related resources of this brain collection 
have been characterized in microarray and anatomical studies (Bloss et al., 2011; Hashimoto et 
al., 2005a; Lewis et al., 2001; Mirnics et al., 2000; Mirnics et al., 2001; Sibille et al., 2009a; 
Sweet et al., 2003). In short, for all cases, a committee of experienced clinical scientists 
examined clinical records, toxicology  and standardized psychological autopsy data (Glantz et 
al., 2000). Individuals were also screened for the absence of neurodegenerative disorders by 
neuropathological examination (Glantz and Lewis, 1997; Sibille et al., 2004; Sweet et al., 2004). 
All procedures were approved by the University of Pittsburgh’s Committee for the Oversight of 
Research Involving the Dead and Institutional Review Board for Biomedical Research. After 
careful examination of clinical and technical parameters, 209 control subjects without DSM-IV 
diagnosis were selected. All six cortical layers of orbitoventral frontal cortex (Brodmann area 47) 
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were harvested and stored in TRIzol (Invitrogen Life Technologies, Carlsbad, CA) at -80˚C until 
processed for RNA isolation. Due to the large cohort size, a sub-cohort was generated for qPCR 
validation based on younger (≤42 years; n=40) and older (≥60 years; n=40) age. These two 
groups did not differ in other measures (Table 3). 
 
Table 3. Characteristics of human postmortem samples used in array and qPCR 
No significant group differences in clinical variables were observed, except for age. 
 
3.2.2 RNA extraction 
Human RNA was isolated from brain homogenate in TRIzol and further purified with RNeasy 
spin columns (QIAGEN, Valencia, CA). RNeasy micro plus kit (QIAGEN) was directly used to 
isolate total RNA from mouse cortices. 
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3.2.3 Gene arrays and expression analysis  
RNA samples were processed for microarray analysis using Affymetrix GeneChip Human Gene 
1.1ST, according to manufacturer’s protocol (Affymetrix, Santa Clara, CA). Gene expression 
data was extracted using Expression Console build 1.2.1.20 and normalized with quantile 
normalization method to eliminate batch effects. To remove age effect on gene expression, each 
expression value was fitted to a regression model using potential confounding covariates. The 
residuals of each gene were further adjusted by a power function regression model for age effect 
only. 
3.2.4 BDNF coexpression network analysis  
Pearson’s correlation values were calculated between BDNF and each gene examined by array. 
The top 200 genes positively correlated with BDNF (R>0.575) were analyzed and visualized 
using Cytoscape (Shannon et al., 2003) (version 3.1.1) with ClueGO plugin (Bindea et al., 2009) 
(version 2.1.7) and further examined with DAVID Functional Annotation Clustering Tool 
(Huang da et al., 2009a, b). The group p-values that are reported in the article are adjusted with 
Bonferroni step down method. 
3.2.5 Animals and drug treatment  
TrkBF616A heterozygote mice (Chen et al., 2005) were obtained from Jackson laboratories (Bar 
Harbor, ME) and intercrossed to generate homozygote mice. Male homozygote mice (9-10 
weeks old) were fed with 25 µM 1NMPP1 or vehicle (0.0003% DMSO) via drinking water for 3 
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weeks and sacrificed. Left and right medial prefrontal cortices were collected and stored at -80˚C 
until RNA isolation. 
3.2.6 Real-time Quantitative Polymerase Chain Reaction (qPCR) 
cDNA was synthesized with total RNA using qScript cDNA supermix (Quanta BioSciences, 
Gaithersburg, MD). PCR products were amplified in triplicate on a Mastercycler real-time PCR 
machine (Eppendorf, Hamburg, Germany) using universal PCR conditions. Results were 
calculated as the geometric mean of threshold cycles normalized to three validated internal 
controls (actin, glyceraldehyde-3-phosphate dehydrogenase, and cyclophilin G). Based on the 
BDNF coexpression network analysis, candidate genes for qPCR verification were selected: (i) 
pan-BDNF; (ii) 2 TrkB isoforms (TrkB-FL, TrkB-T1); (iii) 5 excitatory synapse-related genes: 
vesicular glutamate transporter 1 (vGLUT1), glutamate receptor, AMPA1 (GRIA1), glutamate 
receptor, NMDA 2A & 2B (GRIN2A & 2B), discs large homolog 4 (DLG4, also known as 
PSD95); (iv) 8 inhibitory neuronal genes (presynaptic markers): SLC32A1 (vGAT1), 7 
interneuron markers (SST, NPY, CORT, PVALB, CCK, GAD 1 & 2) (v) 3 postsynaptic GABA 
receptors (GABRA 4/5, GABRB3). 
3.2.7 Statistical analysis  
Gene expression differences were determined by analysis of covariance (ANCOVA) using SPSS 
(SPSS, Inc., Chicago, IL). To determine covariates included in the gene-specific models, each 
nominal factor was tested as the main factor by ANOVA, scale covariates were tested by Pearson 
correlation. Repeated measures were corrected by modified Holm-Bonferroni test and ANCOVA 
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models including significant co-factors were then applied. For the rodent studies, animals were 
separated into two cohorts to minimize age difference. Unpaired t-tests were performed for the 
separate cohorts and then p-values were combined using Stouffer’s z-trend method (Whitlock, 
2005)  and reported in the article. 
3.3 RESULTS 
3.3.1 BDNF and BDNF-associated transcriptome changes in aging human brain 
Large-scale gene expression was obtained by microarray analysis in the orbitofrontal cortex of 
209 postmortem samples from subjects without psychiatric or neurologic illness, ranging from 
16 to 96 years of age. BDNF expression gradually decreased with age (Pearson’s correlation 
value to Age (R=-0.36, p<0.0000001; Figure 7.A). To identify BDNF-related transcriptome 
changes, we calculated Pearson’s correlation values between BDNF and each gene probeset. 
Overall, genes with higher correlation to BDNF showed larger age-related changes (Figure 7.B).   
To investigate biological pathways potentially affected by BDNF, the top 200 genes 
positively correlated to BDNF (R>0.575, whole list is available in Table 8 in Appendix C) were 
analyzed with Cytoscape with ClueGO (Figure 7.C, full annotations are available in Figure 24 in 
Appendix C). Among 75 GO terms with p<0.01, 9 functional groups were identified: synaptic 
transmission (66 genes, p=2.4E-22), neuron projection development (47 genes, p=3.2E-15), 
neuron part (49 genes, p=1.3E-17), neuron development (46 genes, p=5.7E-16), signal release 
(20 genes, p=2.9E-07), dendrite (24 genes, p=1.6E-10), cell-cell signaling (54 genes, p=3.8E-18), 
synaptic vesicle (12 genes, p=3.7E-08), growth cone (9 genes, p=1.9E-05). DAVID Functional 
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Annotation Clustering Tool confirmed that the most enriched gene cluster in the BDNF 
coexpression network included synapse-related genes (enrichment score=6.93). The second and 
third clusters identified by DAVID analysis were also associated with synapse (Figure 7.D and 
Table 9 in Appendix C). Genes in top 3 clusters are related to voltage gated channels 
(CACNA2D1, KCND2, SCN3B, KCNAB1, SCN2A, CACNB1, CACNA1E, CACNG3, 
SCN8A, KCNK1, KCNV1), neurotransmitter receptors (GABRB3, GRIN2B, GABRA4, 
GRIA1, GLRA3, GABRA5, GRIN2A, GABBR2, HTR2A), and synaptic vesicle-related 
molecules (SLC17A7, SVOP, RAB3C, GRIN2B, SYT4, SYT5, SV2B, ATP6V0D1), synaptic 
cell adhesion molecules (NLGN1, NRXN3) (Figure 7.D).  
An important control analysis is to rule out a general effect of age underlying the 
correlation between BDNF and the expression of other genes. Accordingly, we performed the 
same analysis using data in which the effect of age was analytically subtracted (i.e., using age-
residual values). Results indicated very similar patterns of correlation values at the level of 
individual genes, and for the functional clustering analysis: 145 of top 200 were overlapping and 




Figure 7. Age-dependent changes in BDNF expression and identification of BDNF-coexpressed genes 
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(A) Age-related reduction of BDNF in human frontal cortex revealed by array (R=-0.36, p<0.0000001) (B) Example 
of BDNF and age opposite correlations for genes of interest: GABRA5 expression is positively correlated with 
BDNF and negatively with age. (C) Sets of GO terms enriched in top 200 genes correlated with BDNF in human 
frontal cortex as identified by Cytoscape with ClueGO. (D) Synapse related genes enriched in BDNF coexpression 
network as identified by David functional analysis. 
3.3.2 Excitatory and inhibitory synaptic genes demonstrate age-related changes that 
parallel changes in BDNF  
DAVID functional annotation tool revealed that GABA as well as glutamate receptor activity-
related genes were significantly enriched in the top 200 BDNF coexpression network; GABA 
receptor activity-related genes (GO:16917): GABBR2, GABRA4/5, GABRB3 (fold 
enrichment=13.7, p=0.003), glutamate receptor activity-related genes (GO:0008066): GABBR2, 
GRIA1, GRIN2A/2B (fold enrichment=10.6, p=0.006). Therefore, we went back to the 
expression dataset and investigated whether additional markers of excitatory and inhibitory 
synapses undergo aging-related changes in a BDNF-dependent manner. Overall, age-related 
downregulation was observed across excitatory and inhibitory synaptic markers (percentage of 
genes with significant negative correlation to age: 68.4% of GABA synaptic genes, 63.0% of 
glutamate synaptic genes, Table 4), suggesting a general suppression of neurotransmission. 
Although the degrees of correlation to BDNF expression were slightly reduced using age-
residual values, 79 out of 84 synaptic genes showed the same directionality and significance of 
correlation using residual or uncorrected expression values (94% matching; Table 2). Compared 
to excitatory synapse-related genes, inhibitory synaptic markers showed a trend towards higher 
correlation to BDNF (gene expression: p=0.088, age residuals: p=0.072). 
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Table 4. Correlation between age-related BDNF expression and expression level or age-adjusted residual 
expression values of synapse-related genes 
Close correlation to BDNF is maintained after aging effect on gene expression is removed. 
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3.3.3 Validation and extension of age-dependent changes in BDNF, GABA- and 
glutamate-related genes 
To extend and validate microarray results, we performed qPCR with primers for BDNF and 
TrkB genes in a selected cohort of 40 younger and 40 older subjects. The array data did not 
differentiate between the isoforms of TrkB so we included primers for the TrkB-FL and the 
TrkB-T1. Sixteen glutamatergic and GABAergic synapse-related genes were also assessed by 
qPCR. BDNF showed downregulation (-10.7±3.6% compared to young, F=4.44, p=0.038) with 
older age. Whereas expression of the full-length TrkB decreased (-19.1±2.7%, F=27.44, p=1.4E-
06), expression of the truncated form increased in older brain (+21.9±6.8%, F=8.92, p=0.004). 
Most examined synaptic markers displayed lower expression in older subjects (Figure 8.A-D): 
vGLUT1 (-13.8±2.4%, F=12.58, p=0.001), GRIN2A (-22.4±3.8%, F=19.07, p=3.8E-05), 
GRIN2B (-25.9±5.2%, F=9.38, p=0.003), DLG4/PSD95 (-18.9±2.6%, F=19.04, p=3.9E-05), 
SST (-46.2±3.8%, F=49.04, p=8.2E-10), NPY (-21.7±5.0%, F=9.49, p=0.003), CORT (-
37.5±2.7%, F=74.02, p=6.4E-13), CCK (-16.6±3.6%, F=14.23, p=3.2E-04), vGAT1 (-
31.9±4.3%, F=35.33, p=7.9E-08), GAD1 (-12.9±3.6%, F=5.68, p=0.020), GABRA4 (-
14.1±3.6%, F=8.53, p=0.005), GABRA5 (-23.7±2.1%, F=43.36, p=4.8E-09), GABRB3 (-
29.3±2.8%, F=52.73, p=2.7E-10). Overall, the qPCR data replicated the array findings with high 
positive correlation (R=0.74, p=4.8E-04; Figure 26 in Appendix C).  
Notably, the expression of synaptic genes showed the highest correlation to TrkB-FL 
expression among 3 BDNF signaling genes (average R=0.63, p<0.0000001; Figure 8.E), 





Figure 8. qPCR validation of age-related gene expression changes in two different age groups 
(A) Relative expression level (old/young) of BDNF signaling (BDNF, TrkB-FL, TrkB-T1) and (B~D) selected sets 
of synapse-related genes in aged subjects compared to the young (Young: ≤42 years, Old: ≥60 years, n=40/each 
group). (E) Pearson’s correlation between BDNF signaling and synaptic markers in aging cohort (one sample t-test 
to 0, *p<0.05 **p<0.01 ***p<0.001). 
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3.3.4 Temporal blockade of BDNF signaling is sufficient to induce age-like changes in 
inhibitory synapse-related genes 
To investigate if low BDNF signaling is sufficient to induce age-related synaptic gene changes, 
we utilized transgenic mice, TrkBF616A, which harbor a point mutation in the ATP binding pocket 
of TrkB that is selectively blocked by ATP competitive kinase inhibitor 1NMPP1, resulting in a 
blockade of TrkB-mediated signaling (Chen et al., 2005). Three weeks of 1NMPP1 treatment did 
not result in changes in BDNF expression, but increased expression of TrkB-FL (+48.5±11.9%, 
p=0.001) and TrkB-T1 (+30.6±9.5%, p=0.014) in the frontal cortex of TrkBF616A homozygote 
mice (Figure 9.A). Among tested synaptic markers, seven genes showed significant aging-like 
changes: DLG4 (-12.0±3.4%, p=0.016), SST (-35.6±6.0%, p=0.001), NPY (-28.8±4.8%, p=2.4E-
05), CORT (-31.7±4.7%, p=0.003), CCK (-36.6±4.4%, p=0.001), GAD1 (-38.2±4.5%, p=0.016), 
GABRA5 (-17.0±3.8%, p=0.041) (Figure 3.B-D). Glutamate receptors and GABRB3 were 
upregulated: GRIA (+38.6±8.7%, p=0.008), GRIN2A (+55.3±14.4%, p=0.006), GRIN2B 
(+81.6%±22.7%, p=0.001), GABRB3 (+37.8±7.1%, p=0.003) (Figure 9.B and D).  
These results indicate that the temporal blockade of TrkB activity in the frontal cortex of 
adult mice is sufficient to induce an aging-associated pattern in expression of markers for 




Figure 9. Gene expression changes by temporal blockade of TrkB  
(A) Relative expression level (1NMPP1/vehicle) of BDNF signaling (BDNF, TrkB-FL, TrkB-T1) and (B~D) 




Normal brain aging is associated with progressive cellular and structural changes, cognitive 
decline, and increased vulnerability to neurobiological diseases. Reduced BDNF function has 
been suggested as a contributor to the molecular and cellular causes of age-related deficits. In the 
present study, we observed changes in BDNF and TrkB transcripts consistent with reduced 
BDNF function in the older human brain (Figure 7 and 8). The analysis of the BDNF gene 
coexpression network shows that the expression of multiple synapse-related genes is closely 
associated with BDNF function (as measured by BDNF/TrkB-FL/T1 expression; Figure 7) and 
also downregulated with aging (Table 4). Our isoform-specific qPCR investigation revealed that 
all BDNF signaling genes, BDNF, TrkB-FL and TrkB-T1, changed in the direction of lower 
BDNF function in the older human brain (Figure 8). Finally using transgenic mice we 
demonstrated that a transient downregulation of BDNF signaling, through TrkB blockade in the 
adult brain, is sufficient to cause an aging-like gene expression profile, specifically affecting 
GABA-related presynaptic markers (Figure 9). These results extend previous correlative findings 
on age-associated decrement of BDNF and TrkB in elderly humans and animal models (Hassel et 
al., 2008; Hattiangady et al., 2005; Hayashi et al., 2001; O'Callaghan et al., 2009; Romanczyk et 
al., 2002; Silhol et al., 2007; Silhol et al., 2005) in two ways:  first, by delineating in the human 
brain the extend of the putative impact of reduced BDNF signaling on the age-related 
transcriptome, and second, by demonstrating in rodents a causal link between reduced 
neurotrophic support and synaptic-related genes. Finally, the preferential impact or reduced 
BDNF signaling on GABA-related markers (Figure 9) provides insights into the dynamics of 
gene changes with aging and has implications for mechanisms of brain disorders.  
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It is widely accepted that synaptic impairments, rather than neuronal loss, underlie brain 
aging. Human studies have reported breakdown in network connectivity as well as impaired 
white matter integrity with aging (Bishop et al., 2010). Non-human primate studies have 
provided more direct evidence that cognitive impairment might result from the loss of cortico-
cortical synapses in PFC: First, age-associated synaptic loss is most prominent for axospinous 
synapses in layer 3 where cortico-cortical synapses predominate. Second, the extent of synaptic 
loss correlates with the degree of cognitive impairments (Dumitriu et al., 2010).  And lastly, poor 
working memory is associated with a higher incidence of presynaptic boutons harboring 
malformed, donut-shaped mitochondria that form abnormally small synaptic contacts (Hara et al., 
2014). In agreement with these reports, we observed in older brain decrements of expression for 
markers of presynaptic boutons, such as vGLUT1, which is enriched in cortico-cortical axon 
terminals. In vitro studies have shown that BDNF plays a key role in synaptogenesis and 
synaptic maturation, not only for excitatory synapses but also for inhibitory synapses (Kohara et 
al., 2007). The present transcriptome and coexpression network analysis confirmed the close link 
between BDNF and the downregulated expression of many synapse-related genes. These 
correlations remained significant even after gene expression was normalized by aging effect (i.e., 
using age-residual expression values), implying that age-dependent changes in BDNF expression 
mediate, rather than moderate, specific age-related transcriptome changes in the human brain, 
potentially contributing to the observed structural, connectivity and functional changes during 
aging. 
Notably, we show that GABA receptors (GABBR2, GABRA4/5, and GABRB3), 
glutamate receptors (GRIA1, GRIN2A & 2B) and multiple genes associated with both excitatory 
and inhibitory functions are closely linked to BDNF expression and downregulated with age. 
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This overall age-related downregulation of synaptic markers may contribute to maintain brain 
function, namely through adjusting the excitation-inhibition balance with increasing age. BDNF 
regulates many cellular functions related to differentiation, maintenance and plasticity, and is 
thus considered a valid biological candidate to orchestrate such complex changes in the human 
brain. Our postmortem human study provides supporting evidence for low BDNF leading to 
decreased synaptic markers during brain aging. However, these findings do not demonstrate 
causation. In previous studies, high BDNF dependency was observed for interneuron markers in 
constitutive (Guilloux et al., 2012; Tripp et al., 2012) and adult (Glorioso et al., 2006) BDNF 
knockout mice. Yet, constitutive or chronic reduction of BDNF can lead to biological 
compensations and the observed gene expression changes could themselves be the result of those 
compensatory mechanisms. Further, age-related gene expression changes in human seem to be 
more specifically affected by TrkB changes. Utilization of TrkBF616A mice allowed us to address 
causality while circumventing those limitations. Contrary to our expectation that both excitatory 
and inhibitory synaptic genes would be decreased by a temporal TrkB blockade, we observed 
aging-like changes mainly in markers of GABA neurons inhibitory presynaptic functions: SST, 
NPY, CORT, CCK and GAD1. Potential reasons for these findings and implications for aging 
and brain disorders are discussed next. 
Several reasons might account for the differential effect of aging and temporal blockade 
of BDNF signaling. First, species differences might account for the discrepancy; indeed, age-
related alterations in gene expression patterns differ between mice and humans (Loerch et al., 
2008). Second, 1NMPP1 treatment to TrkBF616A mice is known to exhibit a TrkB-null phenotype 
(Chen et al., 2005), so contrary to an aging-related gradual decrease of BDNF function, this 
accelerated dramatic change in BDNF/TrkB activity may be too short for evoking the more 
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gradual and long-term compensatory changes that occur during aging. We believe that this 
temporal de-coupling allowed us here to differentiate the effects of BDNF on markers of distinct 
cell populations. Third and related, interneurons might be more dependent on BDNF than 
pyramidal cells and consequently are more likely to exhibit a response to low BDNF signaling. 
This is consistent with prior findings using constitutive KO lines (Glorioso et al., 2006; Guilloux 
et al., 2012; Tripp et al., 2012). GABAergic cells cannot produce BDNF and rely on BDNF 
supply from other cell population such as excitatory neurons (Cellerino et al., 1996; Gorba and 
Wahle, 1999; Jin et al., 2003; Kohara et al., 2007; Marty et al., 2000; Rocamora et al., 1996). 
Together with the findings from human post-mortem study, the animal data suggests that age-
repressed BDNF signaling may result in lower GABA function, which with time may lead to 
glutamate signaling downregulation to preserve excitatory-inhibitory balance (Figure 10).  
One can assume that this mechanism of low BDNF function - driving synaptic alterations 
without breaking the excitatory-inhibitory balance - is crucial for healthy aging. On the other 
hand, deregulation in this homeostatic mechanism may lead to pathological changes and brain 
disorders. Interestingly, MDD has been associated with reduced central BDNF function 
(Guilloux et al., 2012; Tripp et al., 2012) and with an accelerated pattern of age-related 
transcriptome changes (Douillard-Guilloux et al., 2013). However, these MDD- and BDNF-
related changes have been preferentially associated with altered/reduced pre-synaptic GABA 
function rather than excitatory glutamatergic-related functions (Ding et al., 2015; Guilloux et al., 
2012; Tripp et al., 2012). This suggests that MDD may result from a failure for excitation to 
compensate for BDNF and GABA-related gene changes. This is consistent with an age by 
disease interaction model, where the normal trajectory of age-dependent changes provides 
substrates for pathological changes. This model suggest that whenever those changes occur out 
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of their biological context (e.g., too early) or do not lead to appropriate homeostatic adaptations, 
this may result in biological imbalance and pathophysiological entities (McKinney et al., 2012; 
Sibille, 2013). Here, the mechanism underpinning reduced BDNF during aging was not 
investigated, however, hypermethylation in BDNF gene was observed in older subjects of the 
same cohort (McKinney et al., 2015). It would be interesting to investigate how those (and other) 
age-related regulatory mechanisms are affected in MDD.  
In summary, the findings from these human and mouse studies show that age-related 
reduction in BDNF signaling causes synaptic alterations in the prefrontal cortex, which is 
potentially related to cognitive changes in older subjects. The early event may involve alterations 




First, no gene or cellular functional analysis was performed in this study. Although animal and 
imaging studies imply that synaptic disturbance is the underpinning mechanism of age-related 
cognitive decline, we cannot directly determine if synaptic gene expression changes are 
responsible for functional deficit. Second, gene expression profile was analyzed in tissue 
homogenate containing all 6 layers of gray matter. Considering that age-associated cognitive 
impairment has been suggested to correlate with layer 3 pyramidal neurons, the molecular 
changes might be diluted and information such as cell specific-gene alteration pattern would be 
lost. Finally, functional activity was inferred by RNA analyses and not assessed at the protein 
level, since expression and integrity of small neuropeptides can be affected by many factors 
associated with under human postmortem conditions. 
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Figure 10. Proposed sequence of BDNF-induced brain changes during normal aging 
Results from this study show that brain aging suppresses BDNF and TrkB-FL expression, and promotes TrkB-T1 
expression, all together in the direction of repressing BDNF activity. Studies in rodents with temporal blockade in 
BDNF/TrkB signaling suggest that reduced function in the GABA presynaptic compartment may first occur, leading 
in time to reduced function in excitatory synaptic function, together maintaining homeostasis and 
excitation/inhibition balance. 
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Major depressive disorder is the most common psychiatric disease affecting 350 million people 
worldwide (WHO, 2012). Depressive disorders were the second leading cause of disability in 
2010 (Ferrari et al., 2013) and with low remission and high relapse rates, MDD imposes billions 
of dollars of economic burden on US society (Greenberg et al., 2015; Greenberg et al., 2003; 
Kessler, 2012). MDD is defined as a syndrome of mood dysregulation, physiological symptoms 
and cognitive impairment (DSM-5; American Psychiatric Association, 2013). These 
multifactorial features imply that various brain regions are involved in the pathophysiology of 
disease (Seminowicz et al., 2004).  
Structural and functional abnormalities of the prefrontal cortex (PFC) have been 
consistently reported in MDD. The PFC plays a critical role in cognitive function, working 
memory, emotion regulation and is highly affected by stress (Arnsten, 2009b; Cerqueira et al., 
2007; Cerqueira et al., 2005; Cook and Wellman, 2004; Holmes and Wellman, 2009; McEwen 
and Gianaros, 2011; Radley et al., 2008; Radley et al., 2004; Wellman, 2001). Consistent with 
functional impairment and atrophy (Arnsten, 2009a; Drevets, 2000, 2007; Drevets et al., 1998; 
Drevets et al., 1997; Liston et al., 2006; Tan et al., 2007), human postmortem studies reported 
decreased neuronal body size, spine loss, and decreased cellular density in the PFC of subjects 
with MDD (Kang et al., 2012; Rajkowska, 2000a; Stockmeier et al., 2004a).  
Decreased GABA neurotransmission has been implicated in MDD, suggesting imbalance 
of excitation and inhibition (E/I) in the illness (Levinson et al., 2010; Sanacora et al., 2004; 
Sanacora et al., 1999; Sequeira et al., 2009). Studies from our lab have shown decreased GABA-
related genes in diverse corticolimbic areas including the dorsolateral PFC (dlPFC), amygdala, 
and subgenual anterior cingulate cortex (sgACC) of MDD patients (Guilloux et al., 2012; Sibille 
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et al., 2011; Tripp et al., 2011; Tripp et al., 2012). Downregulation of SST, one of the molecular 
markers of dendritic targeting interneurons, in addition to reduced SST (+) cell number, was 
consistently found across different brain regions, whereas parvalbumin (PVALB), the marker of 
perisomatic-targeting interneurons, remained relatively unaffected.  
One of the mechanisms underpinning this selective vulnerability of SST-expressing 
interneurons could be the loss of local neurotrophic support. BDNF is a neurotrophic factor that 
plays a crucial role in neuronal development, plasticity and maintenance throughout life. MDD, 
prolonged stress and chronic administration of corticosterone reduce BDNF expression (Duman 
and Monteggia, 2006; Dunham et al., 2009; Durany et al., 2001; Dwivedi et al., 2003; Guilloux 
et al., 2012; Hashimoto et al., 2005a; Howells et al., 2000; Mao et al., 2014; Phillips et al., 1991; 
Thompson Ray et al., 2011), which might compromise structural integrity (Radley et al., 2008; 
Radley et al., 2004). GABAergic cells cannot produce BDNF and rely on BDNF supply from 
other cell populations such as excitatory neurons (Cellerino et al., 1996; Gorba and Wahle, 1999; 
Jin et al., 2003; Kohara et al., 2007; Marty et al., 2000; Rocamora et al., 1996). In human 
subjects with MDD, SST reduction is accompanied by BDNF and/or TrkB downregulation 
(Guilloux et al., 2012; Tripp et al., 2012), and potentially accelerated by normal age-
downregulation of BDNF expression (Douillard-Guilloux et al., 2013). Animal studies using 
mice with reduced BDNF expression revealed high BDNF dependency of SST (Glorioso et al., 
2006; Guilloux et al., 2012; Tripp et al., 2012), but the underlying mechanism has not been 
identified.  
Local action of BDNF is closely associated with neural plasticity. In addition to its 
autocrine action regulating dendritic and synaptic plasticity of pyramidal cells (Tanaka et al., 
2008; Wang et al., 2015), BDNF can alter the presynaptic GABA system in a paracrine manner 
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(Bolton et al., 2000; Hyman et al., 1994; Kohara et al., 2007; Ohba et al., 2005; Wuchter et al., 
2012; Yamada et al., 2002). Of the ~300,000 probes tested by microarray, we found that the 
expression of GABRA5 (gamma-aminobutyric acid A receptor, alpha 5), which is specifically 
enriched nearby dendritic GABA synapses (i.e. perisynaptic), showed the highest correlation to 
BDNF level in the human prefrontal cortex (Oh et al., submitted). This suggests that dendritic 
BDNF function may be crucial to maintain normal function of SST cells. Interestingly, BDNF 
transcripts are present in dendrites (An et al., 2008; Baj et al., 2011) and cellular localization of 
BDNF transcripts is highly linked to phospho-TrkB immunostaining pattern (Baj et al., 2011), 
suggesting that BDNF transcripts can be locally translated and act in dendrites. Accumulating 
evidence implies that dendritic BDNF mRNA is closely associated with stress: dendritic BDNF 
transcripts are decreased by stress (Berry et al., 2015; Luoni et al., 2014; Luoni et al., 2015), and 
increased by antidepressant treatment (Baj et al., 2012). Knockdown of dendritic BDNF impairs 
structural integrity of hippocampal neurons (Baj et al., 2011; Orefice et al., 2013). 
In the current study, we first determined whether dendritic BDNF transcripts were 
changed in the PFC of MDD subjects and in the mPFC of mouse exposed to chronic stress, and 
tested whether such changes were linked to dendritic-targeting inhibitory interneuron markers. 
Using small hairpin RNA (shRNA), we knocked down dendritic BDNF mRNA to test whether 
low dendritic BDNF expression is associated with MDD- and stress-related phenotype. Finally, 
we investigated whether enhanced TrkB signaling could prevent and reverse chronic stress-
induced behavioral and molecular changes. We predicted that decreased local neurotrophic 
support at dendrites contributes to selective disturbance in dendritic-targeting GABA 
interneurons and finally results in mood dysregulation. 
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4.2 MATERIALS AND METHODS 
4.2.1 Human postmortem subjects  
Postmortem brains were collected from the Allegheny County Coroner’s Office (Pittsburgh, PA) 
after consent from next of kin. The neuropsychiatric-related resources of this brain collection 
have been amply characterized in microarray and micro-anatomical studies (Bloss et al., 2011; 
Hashimoto et al., 2005a; Lewis et al., 2001; Mirnics et al., 2000; Mirnics et al., 2001; Sibille et 
al., 2009a; Sweet et al., 2003). In short, for all cases, a committee of experienced clinical 
scientists examines clinical records, toxicology exam and standardized psychological autopsy 
data (Glantz et al., 2000). Consensus DSM-IV diagnosis is established for psychopathology, 
medical and social histories, and history of substance abuse. This latter characterization 
incorporates a structured interview, conducted by a licensed clinical psychologist with family 
members of the index subject, to assess diagnosis, psychopathology, medical, social and family 
histories, as well as history of substance abuse. Individuals were also screened for the absence of 
neurodegenerative disorders by neuro-pathological examination (Glantz and Lewis, 1997; Sibille 
et al., 2004; Sweet et al., 2004).  All procedures were approved by the University of Pittsburgh’s 
Committee for the Oversight of Research Involving the Dead and Institutional Review Board for 
Biomedical Research. Upon brain collection, coronal blocks are cut in ~2 cm blocks through the 
rostro-caudal extent of the brain and stored at –80°C. The RNA integrity of each brain is 
assessed by chromatography using the Agilent Bioanalyzer instrument (Agilent Bioanalyzer; 
Santa Clara, CA, USA). After careful examination of clinical and technical parameters, 19 pairs 
of MDD and control subjects were selected (detailed characteristics of the cohort is available in 
Table 10 in Appendix D). Each subject was matched for sex and as closely as possible for age 
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with control subjects. Subject groups did not differ in mean age, PMI, RNA integrity number 
(RIN), RNA ratio, comorbid substance abuse, or brain pH as determined by one way ANOVA 
(p>0.05).  
4.2.2 Animals and unpredictable chronic mild stress  
Young adult C57BL/6J male mice were divided into two groups and submitted to control 
housing condition or UCMS consisting of an 7-week regimen of pseudo-random unpredictable 
mild stressors: forced bath (~2 cm water in cage for 15 minutes), wet bedding, predator odor (1 
hour exposure to fox or bob cat urine), light cycle changes, social stress (rotate mice into 
previously occupied cage), tilted cage (45°), mild restraint (50 mL Falcon tube with air hole for 
15 minutes) and bedding changes. The progression of the UCMS syndrome was monitored 
weekly by assessing the degree of coat state degradation and weight changes for each mouse.  
 
4.2.3 Drug treatment 
To test whether enhanced BDNF signaling can prevent chronic stress-induced 
behavioral/molecular changes, male C57/BL6 mice received intraperitoneal injections of TrkB 
agonist, 7,8-dihydroxyflavone (7,8-DHF, 5mg/kg) or vehicle after 2 weeks of chronic mild stress 
for 5 weeks (n=12/group). Anxiety- and depression-related behaviors were determined with 
cookie test, elevated plus maze, open field and novelty suppressed feeding test. At the end of 
study, the brains were flash frozen on dry ice.  
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4.2.4 Behavioral testing 
After UCMS, common tests for depression and anxiety-like phenotype were conducted. 
Behavior evaluated using the Elevated Plus Maze (EPM) used a cross maze with 2 open and 2 
closed 30×5 cm arms. Time spent in the open arms and percent entries (entries into open arms 
divided by entries into open or closed arm×100) in the open arms was recorded for 10 min to 
measure anxiety-like behavior. The total number of entries into any arm was used as an index of 
locomotor behavior. The Open Field test (OF) was performed with aid of the ANY-maze video 
tracking system for the measurement of anxiety-like behavior. The center of the OF was defined 
as the centermost 51×51 cm arena. The time spent and percent distance traveled (distance in 
center divided by total distance×100) in the center of the arena was recorded for 10 min. The 
total distance travelled was recorded as an index of locomotor activity.  The latency for food-
deprived mice to feed in an aversive, novel environment was be used as an index of emotionality 
in the Novelty Suppressed Feeding test (NSF). Mice were food-deprived for 16 h prior to 
exposure to NSF. Testing was performed in a brightly lit 51×51 cm arena covered in bedding. 
Latency to eat a food pellet placed in the aversive center of the arena was recorded during a 12-
minute session. Food consumption in the home cage (food eaten divided by body weight) during 
5 min following NSF testing and percent weight lost during food deprivation was measured as 
controls for appetite differences. The Cookie Test (CT) is based on the conflict between the drive 
for the stimulus and the neophobic behavior of the mouse and utilizes a device containing three 
aligned compartments with the same dimension (20 × 20 × 20 cm). Mice were first familiarized 
with a chocolate cookie (Keebler® Fudge Stripes, US) 5 days before the first testing. At the time 
of testing, a small amount (2±1 g) of chocolate cookie was placed at the corner of the black 
compartment. The mouse was initially placed in the white compartment of the apparatus. The 
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time of first cookie consumption (bites) was recorded within the 12 min test period. Next day, 
another session of testing was performed. An elongated time prior to cookie consumption was 
interpreted as anhedonia, a habituation deficit or a combination of both effects. After behavioral 
tests, all mice were sacrificed by Avertin overdose. After quick perfusion, brains were extracted 
quickly and flash frozen on the dry ice. 
4.2.5 Emotionality z-score 
To reduce behavioral variabilities which are thought to be caused by natural fluctuations over 
time, we integrated emotionality-related measures across tests as described earlier (Guilloux et 
al., 2011). Z-scoring is a mathematical tool used to normalize results within studies. These values 
“indicate how many indicate how many standard deviations (σ) an observation (X) is above or 
below the mean of the control group (µ)”.The equation is as follows:  z=  
After adjusting directionality of the scores so that increased score values reflected 
increased depressive-/anxiety-like behavior, z-scores of individual tests were averaged for group 
emotionality z-score. 
4.2.6 RNA extraction and Real-time quantitative polymerase chain reaction  
For human studies, all six layers of dlPFC were collected in TRIzol and further purified with 
Qiagen RNeasy spin columns (QIAGEN, Valencia, CA). For mice, mPFC punches were taken 
using 19G corer and processed for RNA extraction with Qiagen RNeasy micro kit. To generate 
cDNA, 100 µg of total RNA was mixed with SuperScript III supermix (Invitrogen, Carlsbad, 
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CA) according to manufacturer’s protocol. PCR products were amplified in quadruplets on a 
Mastercycler real-time PCR machine (Eppendorf, Hamburg, Germany) using universal PCR 
conditions. Results were calculated as the geometric mean of threshold cycles normalized to 
three validated internal controls (actin, glyceraldehyde-3-phosphate dehydrogenase, and 
cyclophilin G). Candidate genes for qPCR verification were (i) 6 BDNF transcript variants: 
BDNF-exon 1, 2, 4, 6, CDS, long 3’ UTR; (ii) 2 TrkB isoforms (FL, T1); (iii) 7 Excitatory 
neuronal gene: vGLUT 1, GRIA1, GRIN 2A & 2B, DLG4; (iv) 12 Inhibitory synapse-related 
genes: 9 presynaptic genes, vGAT1, 8 interneuron markers (SST, NPY, CORT, PVALB, CCK, 
GAD 1 & 2), 3 Postsynaptic (GABRA 4/5, GABRB3). 
4.2.7 Protein isolation, immunoprecipitation, and western blotting 
After micropunch, the remaining frontal cortices were collected in lysis buffer (50mM Tris-Cl, 
150mM NaCl, 1% Triton-X100, 0.1% SDS, 1X phosphatase inhibitor cocktails (P0044; Sigma-
Aldrich, St. Louis, MO,), 1X protease inhibitors (539131; EMD Millipore, Billerica, MA)). 
Protein concentration was measured using a Pierce BCA protein assay kit.  
For p-Trk immunoprecipitation, 500 µg of protein was diluted with PBS to 1 ml and 
incubated overnight at +4ºC with 2.5 µl of phospho-TrkA(Y674/675)/TrkB(Y706/707) antibody 
(4621; Cell signaling technology, Danvers, MA). Immunocomplexes were precipitated with 20 
µl of Protein A/G agarose bead (20412; Life technologies, Grand Island, NY) for 2 hours at 
room temperature and separated on 4-15% gradient gel (4561083; Bio-Rad Laboratories, 
Hercules, CA) under reducing conditions and blotted to a PVDF membrane. After blocking with 
Licor blocking buffer (927-40000; LI-COR Biosciences, Lincoln, NE), membranes were 
incubated with rabbit anti-total TrkB antibody (sc-8316; 1:500, Santa Cruz Biotechnology Inc. 
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Santa Cruz, CA) and mouse anti-actin antibody (A2228; 1:10,000, Sigma-Aldrich, St. Louis, 
MO) at 4 ºC overnight. After rinse with PBST, fluorescent dye-conjugated secondary antibodies 
(LI-COR Biosciences) were treated and visualized using LI-COR Odyssey Infrared imaging 
system.  
4.2.8 Small hairpin RNA, DNA constructs and Adeno-associated virus (AAV) 
Small hairpin RNA (shRNA) sequence targeting ggaaggctcggaagcaccct of long 3’ UTR of mouse 
BDNF was adapted from previous work (Orefice et al., 2013). Lentiviral vectors containing 
shRNA against BDNF long 3’ UTR or scrambled shRNA, and eGFP as a reporter gene were 
purchased from GeneCopoeia (Rockville, MD). AAV9-BDNF long 3' UTR shRNA-GFP and 
control virus with scrambled shRNA were commercially prepared with the U6 promoter 
(Virovek, Hayward, CA). Briefly, Bac-to-bac system (Invitrogen) was used to generate 
recombinant baculoviruses. First, shRNA was sub-cloned into pFastBac shuttle vector and 
transformed into DH10Bac competent bacteria. After antibiotic selection, recombinant Bacmid 
containing E. coli were cultured and miniprep DNAs were prepared. Recombinant Baculovirus 
particles were generated by transfecting Sf9 cells with miniprep DNAs and amplified once. For 
AAV vector production, Sf9 cells were double-infected with recombinant baculovirus containing 
the shRNA and a helper recombinant baculovirus containing the AAV Rep and Cap genes. Three 
days post-infection, the Sf9 cells were harvested and lysed in SF9 lysis buffer (50mM Tris-HCl, 
pH7.8, 50mM NaCl, 2mM MgCl2, 1% Sarkosyl, 1% Triton X-100, and 140 units/ml Benzonase). 
After genomic DNA digestion, cell debris was removed by centrifugation at 8,000rpm for 30 min. 
To purify AAV vectors, the cleared lysates were loaded onto CsCl step-gradient and subjected to 
ultracentrifugation at 55,000 rpm for 20 hours. The viral band was drawn through a syringe with 
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an 18-gauge needle and loaded onto a second CsCl and subjected to linear-ultracentrifugation at 
65,000rpm for 20 hours. Then the viral band was drawn and passed through two PD-10 desalting 
columns (GE HealthCare) to remove the CsCl and detergents and at the same time exchanged to 
PBS buffer containing 0.001% pluronic F-68. Quantitative real-time PCR (qPCR) was performed 
to determine the virus titer with primers corresponding to the target gene. 
4.2.9 Primary culture and transfection of mouse cortical neurons 
Primary cortex neurons obtained from E18 embryos of C57BL/6J mouse were purchased from 
Life Technologies (Cat. No. A15585). After rapid-thaw, 3 X105 viable neurons were cultured on 
poly-D-lysine coated 12 mm coverslips in Neurobasal media (Invitrogen) supplemented with 2% 
B27, 0.5 mM GlutaMAX™-I Supplement, and 1% penicillin-streptomycin. Half of the medium 
was replaced with fresh medium every third day to feed cells. At 7 days in vitro (DIV7), 
transfection was performed using 1 μl of Lipofectamine 3000 (Invitrogen) and plasmid DNA 
(0.5 μg) in 50 μl of OPTI-MEM. Half of the culture media was replaced with fresh media after 3 
days.  
4.2.10 Fluorescent-activated cell sorting (FACS) and RNA knockdown yield test 
After 5 days of transfection, media was removed and rinsed with 500 µL of DPBS twice. 300 µl 
of 0.5% trypsin-EDTA was added to detach cells from the plate. After 10 min at 37C, trypsin 
reaction was stopped by adding 300 µl of saline with 1% BSA, 4 mM EDTA, 20 U/ml of 
DNase1. Cells were collected by centrifugation at 300G, 5 min at 4C) and resuspended in 0.3 ml 
of FACS buffer (PBS, 0.5 % BSA, 2 mM EDTA bisodium salt, 10 U/ml of DNAse1). GFP-
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expressing cells were directly collected to lysis buffer containing microtube by FACSAriaII in 
collaboration with McGowan Institute for Regenerative Medicine Flow Cytometry Facility. 
Total RNA was extracted using Qiagen RNeasy micro kit (QIAGEN, Valencia, CA) following 
the manufacturer's protocol. Total RNA sample was mixed with qScript cDNA supermix 
(Quanta BioSciences) to generate cDNA. PCR products were amplified in triplets on a 
Mastercycler real-time PCR machine (Eppendorf, Hamburg, Germany) using universal PCR 
conditions. Results were calculated as threshold cycles normalized to three housekeeping gene: 
actin, cyclophilin, GAPDH. 
4.2.11 Immunocytochemistry and image analysis 
After 5 days of transfection, cells were rinsed twice with PBS and fixed with 4% PFA for 25 
minutes. After subsequent rinses, cells were stained with GFP (A21311; rabbit anti-GFP (2 
µg/ml), Life Technologies) and MAP2 (M9942; mouse anti-MAP2 (2 µg/ml), Sigma-Aldrich) to 
visualize dendrites of transfected cells. Images were obtained using Nikon 90i microscope and 
the morphology of dendrites were automatically traced and reconstructed by Imaris software 
(Bitplane AG, Concord, MA). Quantification of the total length of dendrites, number of dendritic 
segments, Sholl analysis with concentric circles drawn every 10 μm from the soma were 
performed by the program.  
4.2.12 Animals and stereotaxic surgery 
Young adult C57BL/6J male mice were bilaterally injected with 400 nl of AAV9-BDNF long 3’ 
UTR shRNA-GFP virus or with AAV9-scrambled shRNA-GFP (control) with a titer of ~ 2 X 
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1012 genome copies/ml into the medial PFC (A/P +2.0 mm, M/L ±0.4 mm, D/V -2.0 mm). After 
2-3 weeks of recovery, mice were exposed to UCMS. For gene expression analysis, mice 
received BDNF long 3’ UTR shRNA in one hemisphere and scrambled shRNA in the other for 
intra-subject comparison. 
4.2.13 Immunohistochemistry and image analysis 
Mice were anesthetized and perfused through the heart with PBS, followed by fixative solution 
containing 4% paraformaldehyde in PBS. Fixed brains were removed from the skull, postfixed 
overnight, and then cryoprotected for 24-48 hours in 30% sucrose in PBS. Coronal sections with 
a thickness of 35 µm were collected in six serially adjacent sets and stored at 4°C in PBS with 
0.1% sodium azide.  
After blocking with 10% normal goat serum, 0.3M Glycine in PBS with 0.3% Triton X-
100, sections were incubated with antibodies diluted in PBS containing 0.3% Triton X-100 and 
1% normal goat serum. Antibodies used for immunohistochemistry were as follows: Alexa 
Fluor® 488 conjugated rabbit anti-GFP (1:1000, Life Technologies, A21311), chicken anti-GFP 
(1:1000, abcam, ab13970), rabbit anti-SST (1:200, Santa Cruz Biotechnology, sc-13099), mouse 
anti-PVALB (1:1000, Sigma-Aldrich, P3088), Cy3 conjugated goat anti-rabbit (1:250), Alexa 
Fluor® 568 conjugated goat anti-mouse (1:250), Alexa Fluor® 488 conjugated goat anti-chicken 
(1:250). Immunoreacted sections were mounted onto charged glass microscope slides 
(SuperFrost Plus; Fisher Scientific), air-dried and coverslipped with Vectashield hardset 
mounting media (Vector, H-1400). 
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4.2.14 Statistical analysis  
Gene expression differences were determined by analysis of covariance (ANCOVA) using SPSS 
(SPSS, Inc., Chicago, IL, USA). To determine covariates to include in the gene-specific models, 
nominal factors were each tested as the main factor by ANOVA, scale covariates were tested by 
Pearson correlation, and repeated measures were corrected by modified Holm-Bonferroni test. 
ANCOVA models including significant co-factors were then applied.  
4.3 RESULTS 
4.3.1 Parallel downregulation of BDNF-long 3’ UTR and dendritic targeting interneuron 
markers in the frontal cortex of human subjects with MDD 
The BDNF gene is composed of at least nine exons and makes diverse transcript variants by 
combination of alternative splicing and two polyadenylation sites (Figure 11.A). The spatial 
segregation of BDNF mRNA is encoded by different untranslated regions (UTRs); transcript 
variants with exon 2, 6 and the long 3' UTR can migrate to distal dendrites whereas mRNAs 
containing exon 1, 4 and the short 3' UTR are restricted to the soma (Baj et al., 2011; 
Waterhouse and Xu, 2009) (Figure 11.B; modified from Baj et al., 2011). Therefore, we 
designed primers targeting different UTRs related to cellular localization of BDNF transcripts to 
investigate if depression is associated with defects in specific transcript variants. A primer set 
targeting protein coding sequence (cds) of BDNF was also included to measure total BDNF level. 
Among tested BDNF UTRs, only the long 3’ UTR was significantly decreased in the dlPFC of 
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MDD subjects (-20.8±5.1%, p=0.012, Figure 11.C), suggesting significant decrease of dendritic 
BDNF transcripts.  
A broader panel of tested genes indicated no expression changes for TrkB isoforms and 
excitatory synaptic-related genes. However, inhibitory synaptic genes displayed significant 
disease-related downregulation: SST (-33.9±7.2%, p=4.6E-04), NPY (-32.4±6.0%, p=2.5E-03), 
CORT (-30.8±4.8%, p=8.5E-05), vGAT1 (-28.6±5.1%, p=6.6E-03), GAD1 (-21.8±3.1%, 
p=8.3E-03) GAD2 (-20.8±2.1%, p=8.4E-03), GABRA5 (-20.0±2.7%, p=3.0E-03) (Figure 11.D-
G, p-values are corrected for multiple comparisons). Interestingly, all three dendritic-targeting 
GABA interneuron markers (SST, NPY, and CORT) and GABRA5 were significantly decreased 
in MDD, whereas PVALB and cholecystokinin (CCK), the molecular markers of perisomatic-
targeting interneurons, did not show significant changes, together suggesting selective and 
specific effects of MDD on dendritic-targeting interneurons. 
We previously reported that SST displayed an age-related decline in sgACC of control 
subjects, but not in MDD because of low SST expression in MDD across ages (Tripp et al., 
2011). Similarly, age-related reduction was observed in BDNF-long 3’ UTR, SST and CORT in 
control subjects; however, such gene expression alterations were diminished or decreased in 
MDD (Table 11 in Appendix D). Sex of the patient, antidepressant treatment at time of death, 





Figure 11. MDD-related changes in BDNF transcript variants and synaptic markers in human dlPFC 
(A) Rodent BDNF gene structure and splice variants. (B) Schematic representation of microcircuitry and relative 
cellular distribution of BDNF transcripts. (C) Relative expression level (MDD/control) of BDNF transcripts, (D) 
TrkB isoforms, (E-G) selected sets of synapse related genes (n=19/group; *p<0.05, **p<0.01, ***p<0.001). 
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To investigate if low dendritic BDNF mRNA is associated with inhibitory synaptic gene 
changes, we calculated Pearson’s correlation values between BDNF long 3’ UTR and genes 
changed or unchanged in the brain of MDD subjects. While genes without disease-related 
changes did not show significant correlation, most MDD-related synaptic genes were positively 
correlated to the level of BDNF long 3’ UTR (Figure 12): Pearson’s correlation to BDNF-long 3’ 
UTR: SST (R=0.53, p=6.8E-04), NPY (R=0.49, p=1.9E-03), CORT (R=0.58, p=1.5E-04), 
vGAT1 (R=0.35, p=0.033), GAD1 (R=0.37, p=0.021), GAD2 (R=0.250, p=0.129), GABRA5 
(R=0.47, p=2.7E-03). Average correlation value between BDNF to MDD-related genes was 
0.42±0.11 (p=6.1E-06), mean correlation value to MDD-unrelated genes was 0.10±0.16 
(p=0.092; Figure 12.E). 
In summary, selective downregulation in dendritic BDNF and dendritic-targeting 
interneuron markers were observed in the dlPFC of MDD subjects. Close correlation between 
BDNF long 3’ UTR and GABA synaptic gene expression suggests that that low dendritic BDNF 




Figure 12. Association between BDNF long 3’ UTR and MDD-related synaptic gene changes 
(A) Pearson’s correlation between BDNF long 3’ UTR and SST, (B) NPY, (C) PVALB, (D) CCK. BDNF long 3’ 
UTR is positively correlated with dendritic targeting interneuron markers (SST, NPY), but not with markers of 
perisomatic targeting interneurons (PVALB, CCK). (E) Overall correlation between BDNF long 3’ UTR and MDD-
related or unrelated synaptic markers. Significant positive correlation between BDNF long 3’ UTR level and MDD-
associated gene expression changes suggest contribution of dendritic BDNF to transcriptome alterations (one sample 
t-test to 0, *p<0.05 **p<0.01 ***p<0.001). 
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4.3.2 Chronic stress-related downregulation of dendritic BDNF transcript in the mPFC of 
rodents 
Although chronic stress is a significant risk factor for major depression, MDD is associated with 
a joint contribution of environmental and genetic factors. Furthermore, BDNF can be regulated 
by various etiological factors such as exercise, circadian rhythm, and diet, all factors which 
cannot be controlled in human postmortem studies. Hence, we tested if chronic stress was 
sufficient to induce MDD-like gene expression changes using an animal model of depression, 
UCMS (Unpredictable Chronic Mild Stress). Male C57BL/6J mice were exposed to chronic mild 
stressors or control housing conditions for 6 weeks (n=12/group) and common behavioral tests 
measuring anxiety-/depressive-like behavior were performed. UCMS-induced depressive- and 
anxiety-like phenotype indicated by significantly higher emotionality z-score in stressed mice 
than control (z-score = 0.57, p=2.6E-03; Figure 13.A). Chronic stress significantly increased the 
latency to bite in NSF (control: 120±27s, UCMS: 212±37s, p=0.03) and in the cookie test 
(control: 287±72s, UCMS 471±54s, p=0.03). Individual behavioral test results are available in 
Figure 27 in Appendix D. 
In medial prefrontal cortex (mPFC), long 3’ UTR of BDNF (-24.9±7.5%, p=0.029) and 
CCK (+11.0±3.3%, p=0.045) were significantly changed by chronic stress (Figure 13.B and C). 
Despite significant reduction of dendritic BDNF transcripts, none of the dendritic-targeting 
interneuron markers showed stress-related change (Figure 13.C): SST (-4.3±2.3%, p=0.288), 
NPY (+9.2±7.9%, p=0.201), CORT (-14.6±4.5%, p=0.208) (expression levels of other synaptic 
genes are available in Figure 28 in Appendix D). Due to the discrepancy between human and 
animal results, we calculated Pearson’s correlation values between SST and BDNF long 3’ UTR 
to see if SST is closely associated to BDNF-long 3’ UTR in the rodent brain. A significant 
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positive correlation suggested that close links between SST and BDNF long 3’ UTR exists in the 
mouse tissue (R=0.43, p=0.018; Figure 13.D). Next, we examined whether the depressive-
/anxiety-like trait is associated with gene expression level. Emotionality z-score was negatively 
correlated to both BDNF long 3’ UTR (R=-0.43, p=0.018; Figure 13.E) and SST (R=-0.41, 
p=0.024; Figure 13.F). Nonetheless, PVALB and CCK did not show a significant correlation 
either to BDNF long 3’ UTR or to emotionality z-score: correlation value between PVALB and 
BDNF long 3’ UTR (R=-0.23, p=0.141) and emotionality (R=0.17, p=0.211), correlation value 
between CCK and BDNF long 3’ UTR (R=0.31, p=0.070) and emotionality (R=-0.06, p=0.390).  
Together, chronic stress induced downregulation in dendritic BDNF mRNA, but not in 
SST. These subtle gene expression changes in the stressed mouse brain might be caused by 
differences in timescale; human MDD subjects suffered for years to decades whereas mice were 
exposed to stress for only six weeks. A significant positive correlation between SST and BDNF 
long 3’ UTR suggests that dendritic BDNF function is closely linked to SST-expressing 
interneurons in the mouse brain. In addition, depressive-/anxiety-related traits were inversely 
correlated with both BDNF long 3’ UTR and SST. These data suggest that dendritic BDNF 
expression decreases at the early stage of stress-induced transcriptome changes, and SST 





Figure 13. Chronic stress-related changes of BDNF transcript variants and synaptic markers in mouse mPFC 
(A) Increased depressive-/anxiety-like phenotype in stressed mice compared to control, (B) Relative expression 
level (stress/control) of BDNF transcript variants, (C) inhibitory presynaptic-related genes. Similar to MDD, BDNF 
long 3’ UTR was reduced by chronic stress. (D) Positive correlation between BDNF long 3’ UTR and SST suggest a 
close link between two genes in mouse brain. (E) Significant inverse correlation between emotionality and BDNF-
long 3’ UTR and (F) SST. (n=12/group; *p<0.05, **p<0.01, ***p<0.001) 
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4.3.3 Knock-down of dendritic BDNF transcript is sufficient to induce MDD- and stress-
associated phenotype 
As significant downregulation of BDNF-long 3’ UTR was observed in the prefrontal cortices of 
MDD subjects as well as in UCMS mice, we next investigated whether altered dendritic BDNF 
was causal to the MDD/stress-related phenotype. Structural abnormalities including synaptic loss, 
dendritic shrinkage and atrophy in brains of MDD patients and stressed animals have been well 
documented. To address whether low dendritic BDNF could explain these anatomical changes, 
we utilized shRNA targeting long 3’ UTR of BDNF, which was already verified to decrease 
dendritic BDNF transcripts by other group (Orefice et al., 2013). Using GFP as a co-expressed 
marker gene (Figure 14.A, B), shRNA-expressing primary mouse cortical cells were collected 
with Fluorescence-activated cell sorting (FACS) to assess the knockdown yield of shRNA. qPCR 
showed that shRNA treatment decreased BDNF long 3’ UTR level to below detection limit 
without affecting total BDNF (Figure 14.C). Five days of BDNF knockdown significantly 
impaired dendritic integrity of primary cortical neurons (control: n=14, BDNF long 3’ UTR 
shRNA: n=10). Sholl analysis revealed that the distal dendrite was mainly affected by gene 
manipulation; number of dendrites crossing circles was not different in the proximal dendrite of 
both groups (0~30 µm from cell body), but shRNA expressing cells had smaller number of 
neurites between 40 to 250 µm (Figure 14.D). Furthermore, total dendritic length of shRNA-
treated cells was decreased to 83.6±5.3% compared to scrambled treated neurons (p=0.009, 
Figure 14.E) while number of dendritic segments was unchanged (98.5±13.9%, p=0.91; Figure 
14.F). These data indicate that BDNF long 3’ UTR suppression decreases the length of 
individual branches rather than the branching pattern.   
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Figure 14. BDNF long 3’ UTR knockdown-induced structural changes of primary cortical neurons 
(A) Representative image of primary mouse cortical neuron expressing scrambled shRNA and (B) BDNF long 3’ 
UTR-targeting shRNA. (C) Relative expression (shRNA/scrambled) of BDNF-cds and BDNF long 3’ UTR in 
shRNA expressing cells compared to control. Expression of long 3’ UTR was decreased below detection limit by 
shRNA treatment. (D) Sholl analysis for shRNA-treated and control neurons showed that shRNA treatment 
disrupted integrity of distal dendrite. (E) Relative value of total length of dendrites of shRNA-treated and control 
neurons. (F) Relative value of number of dendritic segments of shRNA-expressing neurons compared to control. 
Total dendritic length was significantly decreased without changes in branch number (control: n=14, shRNA: n=10; 
*p<0.05, **p<0.01, ***p<0.001). 
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To investigate whether decreased BDNF long 3’ UTR is associated with behavioral 
changes, we injected AAV expressing either BDNF long 3’ UTR shRNA or scrambled shRNA 
to the mPFC of wild type mice bilaterally (Figure 15.A). After 2~3 weeks of recovery, baseline 
emotionality was measured. No significant group difference was observed in any behavioral tests 
we performed (scrambled: n=9, shRNA: n=13; Figure 15.E-F). Therefore, we exposed mice to 
chronic stress for 6 weeks to see if low BDNF long 3’ UTR altered stress susceptibility (Figure 
15.B). While body weight was not changed with prolonged stress, we observed progressive 
worsening of coat state, indicating that both groups of mice responded to UCMS. Interestingly, 
shRNA treated mice displayed coat state changes earlier than control group (Figure 15.C, D). 
The behavioral tests performed in UCMS week 6 revealed significantly greater depressive-
/anxiety-related behaviors in shRNA treated mice compared to control. In the open field test, 
shRNA treated mice did not differ from control group in time spent in center in pre-stress period 
(scrambled 54.7±2.9 s, shRNA 42.0±5.8 s, p=0.052), however, shRNA treated mice spent 
significantly shorter time in the center area after stress exposure (scrambled 41.3±5.6 s, shRNA 
26.5±2.8 s, p=0.009. Figure 15.E). Overall emotionality also showed significant group 
differences after stress exposure (scrambled 0.95±0.22, shRNA 1.5±0.17, p=0.029; Figure 15.F). 






Figure 15. Combinational effect of BDNF long 3’ UTR knockdown and chronic stress on behavioral changes 
(A) Representative image of GFP expression following AAV injection in mPFC. (B) Schematic of the experimental 
design. (C) Body weight changes with chronic stress (D) Progressive coat state changes with stress exposure. (E) 
Stress X shRNA interaction on time spent in center in open field test. shRNA treated mice spent less time in center 
after stress. (F) Emotionality z-score. ShRNA showed additive effect on stress-induced emotionality increase 
(scrambled: n=9, shRNA: n=13; *p<0.05, **p<0.01, ***p<0.001). 
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To examine whether knockdown of dendritic BDNF is sufficient to induce MDD-
associated synaptic gene changes, we injected BDNF long 3’ UTR shRNA in one hemisphere 
and scrambled shRNA in the other (Figure 16.A, n=6/group). Mice were sacrificed at 2, 4, and 6 
weeks after surgery, gene expression level was measured and compared in an intra-subject 
manner (Figure 16.B). qPCR analysis revealed that shRNA treatment changed synaptic gene 
expression in a manner similar to the MDD-associated transcriptome profile. Although no 
obvious gene expression changes were found after 2 weeks of shRNA expression (Figure 16.C). 
BDNF long 3’ UTR as well as total BDNF level were significantly reduced in week 4 (Figure 
16.D): BDNF-cds: -24.1±5.9% (p=0.030), BDNF long 3’ UTR: -27.3±11.0% (p=0.013). And 
finally, SST level was changed along with BDNF mRNAs in post-surgery week 6: BDNF-cds: -
52.9±4.9% (p=0.009), BDNF-long 3’ UTR: -40.7±6.6% (p=0.030), SST: -31.2±7.0% (p=0.002) 
(Figure 16.E). In support of the mRNA changes, immunofluorescent signal intensity of SST was 
significantly decreased in shRNA injected region than control region (-5.7±1.7%, p=0.026; 
Figure 30 in Appendix D). A significant positive correlation between SST and BDNF long 3’ 
UTR expression (R=0.66, p=0.009) in week 6 confirmed that reduced BDNF long 3’ UTR is 
responsible for SST changes (Figure 16.F). Again, PVALB did not show such relationship to 
BDNF long 3’ UTR (R=0.05, p=0.433; Figure 16.G). Although total BDNF was significantly 
reduced by shRNA, its expression level was not related to either SST or PVALB (correlation to 




Figure 16. BDNF long 3’ UTR knockdown-related gene expression changes 
(A) Representative image of GFP expression following AAV injection in mPFC. (B) Schematic of the experimental 
design. (C-E) Expression changes in core genes at 2, 4, 6 weeks after surgery. Expression changes in total BDNF 
and BDNF-long 3’ UTR were observed from week 4 and SST changed in week 6. (F-G) Pearson’s correlation 
between BDNF long 3’ UTR and SST/PVALB at post-surgery week 6. Significant correlation to BDNF long 3’ 




We analyzed other BDNF/TrkB isoforms and synapse-related genes in mouse cortices 
from post-surgery week 6. None of the tested genes were altered by shRNA treatment except for 
BDNF exon4 (-37.0±9.5%, p=0.035; Figure 31 in Appendix D). Overall, BDNF long 3’ UTR 
KD-induced gene expression changes were similar to transcriptome profile in MDD (R=0.45, 
p=0.009; Figure 32 in Appendix D). 
In summary, knockdown of dendritic BDNF recapitulated MDD- and chronic stress-
associated phenotypes: impaired integrity of distal dendrites, increased emotionality and reduced 
SST. Our observations that SST reduction occur several weeks after successful knockdown of 
dendritic BDNF, and that shRNA treated mice showed transcriptome profiles more similar to 
MDD than UCMS mice clearly suggest that MDD-induced dendritic BDNF downregulation is 
the cause of GABAergic gene changes. 
4.3.4 7,8-dihydroxyflavone, a selective TrkB agonist prevented development of 
depressive-/anxiety-like behavior by chronic stress, but not through dendritic BDNF 
To test whether stress-induced changes can be prevented by enhanced BDNF signaling, mice 
received daily intraperitoneal injection of TrkB agonist, 7,8-dihydroxyflavone (7,8-DHF), for 4 
weeks starting in the third week of UCMS (Figure 17.A). Drug efficacy of 7,8-DHF was 
confirmed with increased phospho-TrkB in mouse forebrain (relative signal intensity to control: 
2.9, Figure 17.B). 
We found that development of the depression/anxiety-like phenotype was prevented by 
pharmacological potentiation of TrkB with 7,8-DHF. In novelty suppressed feeding, 7,8-DHF 
treatment significantly reduced latency to eat a food pellet (non-stress+vehicle: 120±27 s, 
UCMS+vehicle: 212±37 s, UCMS+7,8-DHF: 114±7 s, group difference between UCMS+vehicle 
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and 7,8-DHF: p=0.013; Figure 17.C). Other behavioral test results are available in Figure 33 in 
Appendix D. Emotionality z-score was also decreased by drug treatment (Non-stress+vehicle: 
0.0±0.2, UCMS+vehicle: 0.6±0.1, UCMS+7,8-DHF: 0.2±0.1, group difference between 
UCMS+vehicle and 7,8-DHF: p=0.035; Figure 17.D.). These data suggest that maintaining 
integrity of BDNF-TrkB signaling is critical for mood regulation.  
Next, we examined whether increased TrkB activity restored UCMS-related gene 
expression changes. While stress did not change TrkB-FL mRNA expression in mPFC, it 
reduced TrkB protein level in the forebrain. Both mRNA and protein showed significant 
upregulation after 4 weeks of 7,8-DHF treatment increased both mRNA and protein (Figure 
17.E-G). Overall, TrkB protein and mRNA showed a significant positive correlation (Figure 34 
in Appendix D). 7,8-DHF treatment recovered stress-related CCK downregulation and 
upregulated GRIN2A, and decreased three GABA receptors (GABRA4, 5 and GABRB3) 
compared to vehicle-treated stressed mice (Table 12 in Appendix D). Neither BDNF long 3’ 
UTR nor SST were changed by drug treatment.  
In conclusion, a chronic mild stress-induced depressive-/anxiety-like trait was prevented 
by pharmacological potentiation of TrkB with 7,8-DHF. Nevertheless, the therapeutic effect of 
7,8-DHF seems to be related to enhanced TrkB activity rather than dendritic BDNF transcript 






Figure 17. Pharmaceutical effect of 7,8-DHF, a selective TrkB agonist, on stress-induced behavioral, 
molecular changes 
(A) Experimental design. (B) Western blot of immunoprecipitated phosphor-TrkB in forebrain of control or 7,8-
DHF treated mice. 7,8-DHF significantly increased p-TrkB in the forebrain of treated mice. (C) Effect of chronic 
7,8-DHF treatment on latency to eat food pellets in novelty suppressed feeding test, (D) overall integrated 
emotionality z-score. NSF and z-score suggest an antidepressant effect of 7,8-DHF. (E) TrkB-FL mRNA level in 
mPFC, (F-G) total TrkB-FL level measured by western blot. TrkB mRNA and protein were significantly increased 




Major depression disorder is a devastating disorder characterized by low mood, anhedonia, 
cognitive deficits and physiological changes. Human and animal studies suggest that impaired 
neural plasticity and GABA dysfunction is associated with the disease; however, the mechanism 
underlying these two phenomena has not been clearly defined. In the current study, we observed 
selective downregulation of dendritic BDNF mRNA without changes in total BDNF level in the 
dlPFC of human MDD subjects and paralleled downregulation of dendritic-targeting interneuron 
markers (SST, NPY, CORT) without affecting perisomatic-targeting interneuron markers 
(PVALB, CCK)  (Figure 11). High correlation between BDNF long 3’ UTR and inhibitory 
synaptic genes suggests that an MDD-related decrease in dendritic BDNF transcripts contributes 
to impairment of dendritic-targeting interneurons (Figure 12). A selective deficit of BDNF long 
3’ UTR was also observed in the mPFC of stressed mice (Figure 13). Although SST expression 
did not show significant changes after 6 weeks of stress exposure, it was positively correlated to 
BDNF long 3’ UTR and showed significant negative correlation to emotionality. Knockdown of 
BDNF long 3’ UTR using shRNA replicated MDD-associated structural (Figure 14) and 
molecular (Figure 16) phenotypes. Obvious depression-/anxiety-like behavioral phenotypes were 
not observed in the shRNA treated mice at baseline (Figure 15); however, a time course study 
revealed that BDNF expression remained unchanged after 2 weeks of AAV expression (Figure 
16). Supportive to the significant BDNF expression changes in post-surgery week 4, shRNA-
expressing mice showed fur degradation earlier than control mice. When the shRNA-treated 
group was divided into two based on their surgery date, group differences in open field test and 
emotionality z-score became significant: Time spent in center (OF)- control (n=9): 54.7±2.9s, 
shRNA-1 (first half, n=7): 40.0±5.4s (p=0.012), shRNA-2 (second half, n=6): 44.42±11.5s); 
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Emotionality z-score- control: 0±0.3, shRNA-1: 0.7±0.6 (p=0.029), shRNA-2: -0.5±0.3 
(p=0.267). Seven weeks of UCMS increased emotionality in both BDNF long 3’ UTR shRNA- 
and scrambled shRNA-treated group; however, the final emotionality was slightly higher in 
shRNA treated mice than control, suggesting that dendritic BDNF KD increased stress 
susceptibility. The fact that group differences in coat state reached maximum at the 5th week of 
UCMS and decreased with prolonged stress suggests that we might have lost the time window to 
see the maximum group difference in behavioral phenotype. Pharmacological activation of TrkB 
with 7,8-DHF prevented development of depression-/anxiety-like behaviors following chronic 
stress, but the anti-depressant effect seems to be mediated by potentiated TrkB function rather 
than normalization of dendritic BDNF and GABA system (Figure 17). 
4.4.1 Contribution of low dendritic BDNF on reduced neuroplasticity and function in the 
dlPFC of depressed subjects 
Knockdown of BDNF long 3’ UTR was sufficient to induce stress- and MDD-associated 
morphological changes in cortical neurons. In agreement with a human postmortem study 
reporting reduced length of dendritic processes but no change in the number of processes in 
basilar dendrite of deep layer 3 pyramidal neurons in dlPFC of subjects with psychiatric illnesses 
including MDD (Glantz and Lewis, 2000) and animal studies showing stress-induced 
morphological changes mainly occur on the distal portion of apical dendrites (Bloss et al., 2010; 
Bloss et al., 2011; Cook and Wellman, 2004; Radley et al., 2008; Radley et al., 2004), small 
hairpin RNA targeting BDNF long 3’ UTR induced retraction of distal dendrites of primary 
cortical neurons.  
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In addition to the impaired neuronal plasticity, dendritic BDNF downregulation is known 
to induce functional and behavioral abnormalities such as impaired long term potentiation (An et 
al., 2008), learning and memory (Stein et al., 2006). Studies on the genetic polymorphism of 
BDNF also corroborate the idea that the dendritic action of BDNF is essential to structural 
stability and normal brain function. The most common single nucleotide polymorphism in 
humans at codon 66, resulting in the Val to Met substitution, has been implicated in cognitive 
impairment (Bath and Lee, 2006), defective fear extinction (Soliman et al., 2010), and increased 
susceptibility to psychiatric diseases (Gatt et al., 2009). Human BDNF Val66Met knock-in mice 
exhibit impairment in the dendritic transport of BDNF mRNA (Chiaruttini et al., 2009; Mallei et 
al., 2015), decreased activity-dependent BDNF secretion (Egan et al., 2003), decreased dendritic 
complexity and anxiety-like behavior that is not normalized by fluoxetine (Chen et al., 2006), 
impaired synaptic plasticity in the central amygdala (Galvin et al., 2015), mPFC (Pattwell et al., 
2012), hippocampus (Ninan et al., 2010) and lower ketamine-induced synaptogenesis in the PFC 
(Liu et al., 2012). Our finding that emotionality is significantly correlated to BDNF long 3’ UTR 
expression provides evidence that dendritic BDNF function is important for the mood regulatory 
system.  
Then how can the loss of dendritic BDNF and associated structural changes contribute to 
functional abnormalities? One of the mechanisms could be the loss of the distal dendrite itself. 
The degree of structural changes is negatively related to cognitive flexibility and working 
memory performance (Hains et al., 2009). Stress-related structural alterations are reversed in the 
absence of stress (Bloss et al., 2011) and this structural recovery is accompanied by functional 
restoration (Goldwater et al., 2009). Furthermore, serotonin receptors are highly expressed in the 
distal portion of the dendrite (Liu and Aghajanian, 2008). Repeated mild restraint stress and 
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chronic corticosterone treatment decrease 5-HT-induced excitatory postsynaptic currents and this 
effect is negatively correlated with the length of apical dendrites and spine density on the distal 
branches (Liu and Aghajanian, 2008). With dendritic shrinkage, neurons might lose serotonin 
synapses and connections to other brain areas. Our finding that shRNA-treated mice spent less 
time in the center of the open field than controls suggests that dendritic BDNF KD may 
compromise mPFC function to suppress amygdala, the fear center. Second, defects in activity-
dependent BDNF supply might play a role. Recent study found that over 2,000transcripts were 
localized in dendrites and/or axons, maybe for faster protein supply on demand by local synaptic 
translation (Cajigas et al., 2012). Not only does long 3’ UTR (+) BDNF mRNA exist in the 
dendrite; it stays dormant in resting state, yet binds to a polyribosome responding to neuronal 
activity (Lau et al., 2010). Given that MDD is considered a disease of adaptation, impaired 
activity-dependent neuroplasticity may underlie the inability to cope with stress. A third possible 
mechanism could be through reduced GABA transmission. Knockdown of dendritic BDNF 
transcript and/or blockade of dendritic transport downregulates GABA receptors and GABA 
synthesizing enzymes (Stein et al., 2006; Waterhouse et al., 2012). These data imply that the 
functional outcome may derive from low GABA transmission at least in part. Related, further 
discussion continues in the next section. 
 
4.4.2 Close link between dendritic BDNF transcripts and dendritic-targeting interneurons 
and its implication for pathology of major depressive disorder 
SST and PVALB are expressed in distinct classes of cortical interneurons. Multiple lines of 
evidence imply that BDNF/TrkB signaling plays a crucial role in interneuron development and 
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maintenance of GABA function. Our studies consistently found that low BDNF function is 
responsible for reduced GABAergic genes in the depressed brain (Guilloux et al., 2012; Sibille et 
al., 2011; Tripp et al., 2011; Tripp et al., 2012). As TrkB is predominantly expressed in PVALB 
(+) interneurons rather than other interneuron populations (Cellerino et al., 1996; Gorba and 
Wahle, 1999), higher BDNF dependency of SST than PVALB raised questions about the 
mechanism. Our current study provides a clue that dendritic BDNF function is associated with 
neuronal plasticity, behavior and SST expression, which may indicate the health and function of 
dendritic-targeting interneurons.  
To date, it is not clearly defined how dysfunction of SST (+) interneurons contribute to 
pathophysiology of mood disorders. Distal dendrites mainly receive inputs from other cortical 
areas and regulation of dendritic excitability is crucial for functional computations (reviewed in 
(Larkum, 2013)). Considering that dendritic excitation mainly occurs in actively-behaving 
animals, one can assume that proper control of activation/inactivation of dendrite is crucial for 
regulation of active behavior. For instance, SST (+) interneurons in barrel cortex are inactivated 
during active whisking which leads to increased excitability for the sensorimotor stimuli (Gentet 
et al., 2012). In the BLA during contextual fear learning, SST (+) interneurons are inactivated by 
multisensory environmental context (conditioned stimulus, CS), whereas aversive event 
(unconditioned stimulus, US) inactivates both PV (+) and SST (+) interneurons (Tovote et al., 
2015; Wolff et al., 2014). In the hippocampus, US activates CA1 dendritic targeting interneurons 
such that pyramidal cells do not receive aversive sensory signal from entorhinal cortex during 
conditioning (Lovett-Barron et al., 2014). Loss of dendritic inhibition caused by dysfunctional 
SST (+) interneurons may result in failure to discriminate different stimuli. Furthermore, hyper-
excitability of pyramidal cells may potentially contribute to sustained arousal and vigilance.  
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Figure 18. Proposed model 
Results from current study suggest sequential events associated with MDD-related brain changes. First, prolonged 
stress induces selective deficit of dendritic BDNF indicated by low BDNF long 3’ UTR expression in the PFC. 
Reduced BDNF supply to dendritic compartments and GABA interneurons targeting distal dendrites will lead to 
impaired function of dendritic-targeting interneurons (e.g. downregulation of SST and GABA synthesizing enzyme), 
and disrupted dendritic integrity, and finally, results in mood dysregulation. 
Combining current knowledge and our experimental results, we propose a biological 
model linking low BDNF, impaired neural plasticity and GABA dysfunction, three phenomena 
commonly observed in the PFC of MDD subjects and stressed animals (Figure 18). MDD and 
stress may disturb dendritic BDNF, which leads to low neurotrophic supply to dendrite and 
dendritic targeting interneurons. Reduced dendritic BDNF signaling may contribute to low 
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GADs expression (i.e. low GABA production) and decreased dendritic complexity, finally 
culminating in affect dysregulation. To the best of our knowledge, this is the first study 
investigating the mechanism underlying the high BDNF dependency of dendritic-targeting 
interneurons observed across diverse brain diseases. Results from this study could have a major 
impact on our understanding of BDNF function in normal and disease-state subjects. 
In conclusion, our results provide evidence that MDD-related downregulation of 
dendritic BDNF contributes to selective impairment of dendritic-targeting interneurons in 




5.0  GENERAL DISCUSSION 
MDD is a serious mental illness associated with high comorbidity, poor quality of life, 
and considerable economic burden; however, the detailed biological mechanisms are far from 
being understood. Evidence suggesting low BDNF function and GABA deficits are widely 
reported in MDD brains at multiple levels ranging from molecule to function, although these two 
lines of evidence have been mostly investigated separately. The research in this dissertation 
investigated a mechanism underlying a close link between BDNF signaling and GABA 
dysfunction using translational approaches encompassing cell, animal and human postmortem 
studies. We demonstrate that GABA interneuron markers display different BDNF dependencies 
which may be involved with local action of BDNF, at least in part, and that different interneuron 
populations are implicated in the disease in a region-specific manner. We also show that, distinct 
from related mechanisms occurring during normal aging of the brain, the ability to maintain E/I 
homeostasis may be impaired in the brain of MDD subjects. In the following sections, I 
summarize our findings and discuss their implications for our understanding of disease 
mechanisms. I also discuss limitations of the current studies and possible future directions. 
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5.1 BDNF- AND GABA-RELATED GENE CHANGES IN THE DLPFC AND SG-ACC 
OF MDD PATIENTS 
Growing evidence suggests that dysfunction of corticolimbic circuitry is implicated in MDD. 
Reduced gray matter volume (Drevets, 2000), impaired functional connectivity to other brain 
regions (Mayberg, 1997; Siegle et al., 2007), activity changes in disease state (Alcaro et al., 
2010; Fitzgerald et al., 2007) and in treatment response (Mayberg, 2002; Mayberg et al., 1999) 
have been observed in the sgACC and dlPFC of depressed brains. Impaired E/I balance, 
potentially caused by GABA dysfunction in these brain areas has been thought to be associated 
with the clinical symptoms of affect dysregulation (Sibille et al., 2011; Tripp et al., 2011). Guilloux 
et al showed a close association between MDD-related GABAergic gene changes and low BDNF 
function in the female amygdala (Guilloux et al., 2012). Therefore, we investigated whether BDNF 
signaling is responsible for expression changes of GABAergic genes in these two brain regions 
in male and female MDD subjects (Chapter 2 and 4).  
Our data suggest low BDNF signaling and reduced GABA function in both brain areas. 
Yet, the gene profile displays similarities as well as differences: SST, NPY, CORT, GAD1 and 
GAD2 were commonly decreased. However, PVALB was selectively decreased in the sgACC. 
The BDNF signaling module also showed regional differences. Whereas only dendritic BDNF 
(long 3’ UTR–containing) mRNA was altered in the dlPFC, the sgACC was related to changes in 
TrkB rather than BDNF (Table 2 and Figure 11, summarized in Figure 19). These data are in 
agreement with animal studies that PVALB expression depends on the expression of TrkB 
(Hashimoto et al., 2005a) whereas SST and NPY are highly BDNF-dependent (Glorioso et al., 
2006; Guilloux et al., 2012).  
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SST, NPY, CORT are expressed in the overlapping populations of interneurons that 
innervate the dendritic compartment of pyramidal cells and regulate incoming information from 
other cortices. In contrast, PVALB is expressed in the fast-spiking, perisomatic-targeting 
interneurons which regulate the output of targeted neurons. Expression changes in interneuron 
markers are thought to reflect the functional alterations of the corresponding interneuron group. 
Hence, one can assume that perturbed GABA inhibition caused by different interneuron subtypes 
may have different consequences for the sgACC and dlPFC. The hypothesized contribution of 
GABA dysfunction in these two brain areas is discussed in the conclusion (5.4) and further 
reviewed elsewhere in the context of internal and external awareness (Northoff and Sibille, 2014). 
 
Figure 19. Region-specific expression changes in GABAergic genes 
 99 
5.2 LESSONS FROM NORMAL BRAIN AGING  
5.2.1 Impaired homeostatic plasticity: differences between normal aging and pathological 
changes in the brains of MDD subjects 
While the incidence rate of clinical depression varies depending on the diagnostic criteria, 
depressive symptoms are commonly found in the older subjects. Previous studies in our lab 
showed that great portion of age-regulated genes in the human brain is reported to be associated 
with various neurobiological disorders (Glorioso et al., 2011), suggesting that the brain becomes 
more prone to illness with age. However, not every old subject develops psychiatric or 
neurodegenerative disorders.  
In paper 2, we studied the role of BDNF in healthy brain aging to gain insights into its 
role on pathological brain changes. We found that aging was associated with changes in both 
inhibitory and excitatory synapse-related genes (Table 3, Figure 8). The concurrent expression 
changes in glutamatergic- and GABAergic-genes imply that the E/I balance is well-maintained 
during normal aging. In contrast, a meta-analysis integrating eight independent microarray 
studies performed with different cohorts, different brain regions and platforms shows that MDD 
is associated with preferential changes in GABA-related genes rather than excitatory synaptic 
gene changes (Ding et al., 2015).  
Neurons maintain appropriate levels of activity by adjustment of synaptic strength and 
intrinsic cellular excitability. Recent studies suggest the involvement of dynamic crosstalk 
between excitatory and inhibitory neurons in these processes. Following chronically reduced 
network activity, pyramidal cells restore their excitability to control levels by increasing 
amplitude of miniature excitatory postsynaptic currents (mEPSCs) (Rutherford et al., 1998), or 
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decreasing miniature inhibitory postsynaptic currents (mIPSCs) or spontaneous IPSC amplitude 
(Kilman et al., 2002; Rutherford et al., 1997; Swanwick et al., 2006). On the other hand, 
prolonged activation of network activity increases the numbers of excitatory synapses on 
interneurons as well as GABAergic synapses on pyramidal cells (Lin et al., 2008; Spiegel et al., 
2014). BDNF appears to play an important role in homeostatic plasticity, because exogenous 
BDNF application or an antibody against TrkB prevents or recapitulates these compensatory 
changes, respectively. 
Our study with pharmaceutical blockade of TrkB activity showed that low BDNF 
signaling impacts the GABA system first (Figure 9). The same event might happen in brain 
aging as well as in MDD; however, the compensatory changes may not occur in the pathological 
condition for some reason. Together, the absence of excitatory compensation might be one of the 
core features of neuropathology of MDD (See detailed description in Chapter 2). 
5.2.2 Dendrite: the link between SST and BDNF  
Human and animal studies consistently indicate that SST downregulation accompanies BDNF 
and/or TrkB changes. PVALB is also affected by BDNF function, but is not directly BDNF-
dependent. Glorioso et al suggested that interneuronal gene expression is regulated in a complex 
manner (Glorioso et al., 2006) but this model has not been tested yet. 
In paper 2, we tried to find a molecular link between BDNF and SST using microarray 
data from the prefrontal cortex of control subjects through gene coexpression network analysis, a 
useful tool to identify a functional module, i.e., a set of genes that are involved in a common 
function. BDNF coexpression network analysis revealed that SST and GABRA5 were closely 
associated with BDNF function. Intriguingly, GABRA5 displays the highest correlation among ~ 
 101 
300,000 probes obtained with the arrays. This data leads us to hypothesize that the local action of 
BDNF may play a role in differential regulation of distinct interneuron populations. This 
proposed mechanism was tested in Chapter 4 and seems to be true, at least in the PFC, based on 
the experimental results.  
5.3 LESSONS FROM ANIMAL STUDIES 
5.3.1  Various BDNF dependency of GABA-related genes and implications for the stress 
model 
Throughout studies, we utilized mouse models to address the questions of whether and 
how BDNF regulates GABAergic genes (results are summarized in Figure 20). Various BDNF 
dependency of GABA related genes, and possible sequential events were revealed by different 
animal models.  
It seems obvious that SST, NPY, CORT have a higher BDNF dependency than PVALB. 
All these three interneuron markers changed by constitutive BDNF knockdown (BDNFHet and 
BDNFKIV; Table 1) as well as by temporal TrkB blockade in adult brain (TrkBF616A; Figure 9). 
Virus-mediated BDNF long 3’ UTR interference provides evidence that low BDNF-induced SST 
downregulation happens earlier than that of the other two genes, NPY and CORT. This data is 
further supported by results of a coexpression network analysis in which SST was the only 
dendritic-targeting interneuron marker included in the top 200 genes closely linked to BDNF 
function. 
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GAD2 is enriched in synaptic boutons whereas GAD1 is expressed across all cellular 
compartments of interneurons.  Given that exon IV containing BDNF transcripts are restricted to 
soma (Pattabiraman et al., 2005), it is possible that selective change of GAD2 in BDNFHet 
compared to BDNFKIV (Table 1) might be caused by perturbed dendritic BDNF function.  
Three weeks of TrkB blockade in a developed brain was sufficient to change all three 
interneuron markers as well as GAD1 (Figure 9). Considering that TrkB binds to not only BDNF 
but also NT-3 and 4, it is not surprising that TrkB activity blockade shows greater impact than 
BDNF knockdown. No change was observed in PVALB expression in animal experiments, 
suggesting that PVALB is the most resistant one among the GABAergic genes tested in my 
dissertation study. 
 
Figure 20. Different GABAergic genes changed in each mouse model 
5.3.2 Stress-induced downregulation of BDNF, the cause of impaired GABA circuitry 
Postmortem studies are useful for identifying biological factors relevant to the disease; 
however, they only allow us to see the outcome of pathological changes. Therefore, it is essential 
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to use animal models to delineate neuropathological changes related to the disease. In chapter 4, 
I used the UCMS mouse model of depression to investigate stress-related changes in BDNF and 
GABAergic genes. As discussed earlier, presumably because of shorter duration of stress 
exposure than humans experience in the context of the disease, we did not find many differences 
in the UCMS mouse brain. Nonetheless, a clear finding from the UCMS mouse model is that a 
BDNF reduction is one of the earliest events following chronic stress exposure in the prefrontal 
cortex (Figure 13). These gene changes may be responsible for anatomical (Figure 14), 
behavioral (Figure 15), and molecular changes (Figure 16) observed in brains of human MDD 
subjects and stressed mice (more detailed discussion is available in Chapter 4).  
5.4 LIMITATIONS AND FUTURE DIRECTIONS 
Most of the limitations of Chapter 2 and 3 have already been covered in each respective chapter. 
Here, I will discuss limitations and future directions of Chapter 4 in addition to common 
limitations across studies.  
 
5.4.1 Confirmation of cell type specific alterations  
In all of the three studies, we utilized total RNA from brain homogenates to analyze gene 
expression changes. Interneuron markers like SST and correlation profiles provide some 
evidence about population-specific impairments; however, it is hard to define the cellular origin 
for other common GABAergic transcripts changes. Gene expression analysis with laser 
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microdissection-collected SST (+) and PV (+) cells will be used in future work to provide further 
in-depth information. 
5.4.2 Identification of the cause of selective downregulation of BDNF long 3’ UTR in 
MDD 
We observed a selective decrease in BDNF long 3’ UTR in MDD and mouse brains after chronic 
exposure, but the underlying mechanism was not yet investigated in this study. As the 3’ UTR is 
a common target of trans-acting factors, changes in such molecules are of interest. For instance, a 
recent study identified several micro RNAs (miRNAs) regulate BDNF long and short 3’ UTRs 
(Varendi et al., 2014). HuD, a neuronal RNA binding protein, is reported to interact with BDNF 
long 3’ UTR (Allen et al., 2013) and promote dendritic translation of BDNF long 3’ UTR (+) 
mRNA (Vanevski and Xu, 2015). Therefore, the level of BDNF long 3’ UTR targeting miRNA 
and HuD should be measured in future studies.  
5.4.3 Confirmation of dendritic trafficking of human long 3’ UTR (+) BDNF mRNA 
While dendritic trafficking of long 3’ UTR (+) BDNF transcripts was observed in primary mouse 
neurons, it has not been tested in human brains. Since primary human neuronal culture is not 
technically available, alternative experiments such as expressing a fusion protein, GFP-human 
BDNF short or long 3’ UTR, in rodent primary cortical neurons could be performed to address 
this question. 
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5.4.4 Confirmation of effect of BDNF-long 3’ UTR knockdown on dendritic complexity   
The effects of BDNF long 3’ UTR knockdown on dendritic stability was only 
investigated in vitro, not in vivo. Although studies suggest that autocrine action of BDNF is 
critical for dendritic stability (English et al., 2012; Wang et al., 2015), BDNF from other cells 
also can play a role. We were able to see strong marker gene (GFP) expression in dendrites of 
virus-infected neurons (Figure 30). However, the density of GFP-expressing neurons was too 
high to analyze the dendritic structure of an individual cell. Therefore, a small amount of viruses 
should be injected into the mouse cortex to obtain sparsely distributed infected neurons 
displaying Golgi-like GFP staining.  
5.4.5 Confirmation of gene expression changes in protein level 
Although we examined protein expressions of key genes (BDNF in Chapter 2, phospho-TrkB in 
Chapter 3 and 4, SST immuno-signal intensity in Chapter 4), most gene expression was only 
measured with qPCR. There were two reasons that I focused on the mRNA analysis. First, 
protein expression analysis in human postmortem brain is quite challenging because of the long 
postmortem interval which causes loss of post-translational modifications and protein 
degradation. I tried immunoblot against total TrkB for Chapter 2, but could not find an optimal 
condition. Second, due to the small size of mouse brains, I could not extract a sufficient quantity 
of protein from tissue punches to perform a protein assay. 
Nonetheless, the functional implications of mRNA changes can only be confirmed with 
concurrent protein level changes. Furthermore, post-translational modifications such as 
phosphorylation, acetylation, and proteolytic cleavage also can change protein function. More 
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sensitive protein-detection methods than immunoblot, such as ELISA and selected reaction 
monitoring, will help to overcome this limitation.  
5.4.6 Identification of regulators of homeostatic plasticity 
We suggested that disturbed homeostatic plasticity would be one of the main differences 
between normal brain aging and pathological brain changes.  The underpinning mechanism is not 
clear, but disturbed transcription factors could be a good candidate. A recent study found that a 
decreased number of spine synapses in the dlPFC of MDD subjects was associated with an 
elevated level of GATA1 which represses transcription of synapse-related genes (Kang et al., 
2012). Indeed, several transcription factors have been implicated in homeostatic plasticity. For 
example, CREB mediates activity-regulated transcription in response to calcium influx.  MEF2 
activates transcription of proteins that disrupt synaptic protein complexes and reduce synapse 
number (reviewed in (Flavell and Greenberg, 2008)). Npas4 is upregulated in both excitatory and 
inhibitory neurons in response to sustained network activity; however, the transcription factor 
activates distinct transcription programs in a cell type-specific manner (Spiegel et al., 2014). 
Determination of common promoter elements in the excitatory synapse-related genes selectively 
reduced in aged brains could be used to find candidate transcription factors dysregulated in MDD.  
5.4.7 Verification of the influence of low BDNF signaling on E/I balance 
I argued that the E/I balance is impaired by low BDNF expression (BDNF knockdown or 
knockout mouse) and short-term TrkB blockade (TrkB transgenic mouse) based on selective 
gene expression changes in GABA interneuron markers. However, like excitatory neurons, 
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interneurons receive excitatory as well as inhibitory input. Simple expression changes in synaptic 
function-related genes do not identify the precise circuits which are dysregulated. Therefore, 
synaptic connectivity should be investigated with morphometric analysis using electron 
microscopy, and synaptic function needs to be addressed by analyzing synaptic protein clustering 
patterns. Measurement of electrophysiological properties may provide further information about 
functional changes of each cell population. If my hypothesis is correct, the IPSCs elicited by SST 
(+) interneurons would be selectively reduced after genetic/pharmaceutical manipulation while 
IPSPs activated by PVALB cells remain unchanged. 
5.5 CONCLUSION AND PROPOSED MODEL 
MDD is characterized by a syndrome encompassing diverse physiological and emotional 
symptoms, indicating involvement of multiple brain regions. The goals of this dissertation were 
first to characterize the molecular specificities, and then to investigate mechanisms linking two 
different hypotheses implicated in the pathophysiology of MDD; (1) low neurotrophic factor and 




Figure 21. Proposed model of brain region-specific cellular microcircuit changes 
SST cells innervate the dendritic compartment of pyramidal cells and regulate levels of excitatory input from other 
cortical areas. PVALB neurons target the cell body of pyramidal cells and regulate signal output. Region-specific 
BDNF signaling changes in MDD will lead to population-specific GABA neuron disturbance, which finally results 
in distinctive input/output changes in the sgACC and dlPFC (modified from (Northoff and Sibille, 2014)).  
Integrating a model suggested in a research review (Northoff and Sibille, 2014) and 
findings from my dissertation study, I propose a model of impaired function of SST- and 
PVALB-expressing cells as a downstream consequence of reduced local BDNF signaling. In the 
dlPFC of depressed subjects, there is a selective disturbance in dendritic BDNF which results in 
low neurotrophin supply to SST interneurons. Impaired function of SST (+) interneurons might 
compromise their ability to provide tonic inhibition to pyramidal cells, which results in increased 
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information input. However, BDNF supply to PVALB (+) cells remains intact; therefore, signal 
output from pyramidal cells maintains a proper level. On the other hand, in the sgACC of MDD 
subjects, the function of both interneuron groups is disrupted because of general downregulation 
of TrkB, and sgACC become hyperactive in general (Figure 21). 
This impaired cellular circuit may contribute to functional impairment at the regional 
level, and alterations in both brain areas may give rise to improper informational computation 
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INTRODUCTION 
Among elderly individuals, depressive symptoms are common and burdensome. Approximately 
1% of individuals over the age of 65 meet criteria for major depressive disorder (MDD), as 
defined by the diagnostic and statistical manual of mental disorders, fourth edition, text revision 
(DSMIV-TR; American Psychiatric Association, 2000) a prevalence lower than that in younger 
adults (Kessler et al., 2003). Another 15–25%, however, experience depressive symptoms that, 
while not meeting criteria for MDD, do cause significant distress and interfere with daily 
functioning (Koenig and Blazer, 1992). In this article, the term late-life depression (LLD) will be 
used to refer to individuals over the age of 65 who for the first time in their lives meet criteria for 
MDD or display clinically significant depressive symptoms. Individuals with LLD experience 
greater functional disability (Dombrovski et al., 2007) and cognitive decline (Lenze et al., 2005) 
than those without. Further, they are at increased risk of morbidity and mortality from medical 
illness (Ganguli et al., 2002). LLD also appears to contribute to increased rates of suicide among 
older individuals (Van Orden and Conwell, 2011). 
The biological substrates of LLD are being characterized and several hypotheses for the 
etiology and pathophysiology of LLD have been proposed, including the vascular hypothesis 
(Alexopoulos et al., 1997), inflammation hypothesis (Alexopoulos and Morimoto, 2011), and 
dementia prodrome hypothesis ((Byers and Yaffe, 2011); reviewed in (McKinney and Sibille, 
2013)). Here, we propose an alternative and complementary hypothesis, which we termed the 
age-by-disease biological interaction hypothesis of LLD. Central to this hypothesis is the concept 
of molecular aging of the human brain. An earlier version of this hypothesis has been described 
elsewhere (McKinney and Sibille, 2013). 
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MOLECULAR AGING OF THE HUMAN BRAIN 
Despite its critical importance to a population that is growing older, “normal” brain aging is 
understudied. This may be due to the often expressed, but false belief held by many that aging is 
inescapable, broad-ranging and non-specific. Studies that have investigated biological aging have 
revealed specific changes and thus avenues for intervention. At the cellular level in the human 
brain, morphological and stereological studies reveal a decrease in neuron volumes, a small loss 
or no change in cell numbers (Morrison and Hof, 1997; Pakkenberg and Gundersen, 1997), and a 
progressive thinning of cortical thickness, affecting both gray and white matter (Resnick et al., 
2003; Sowell et al., 2003). Similar structural changes with age have been demonstrated in the 
brains of animal models (Jucker and Ingram, 1997; Peters, 2002). At the molecular level in 
animal models, less than 10% of brain-expressed genes exhibit age-related changes in gene 
expression (Blalock et al., 2003; Jiang et al., 2001; Lee et al., 1999; Lee et al., 2000; Sibille et al., 
2007). Similar numbers have been reported in studies of human tissue (Avramopoulos et al., 
2011; Lu et al., 2004). In one such study of human tissue from the prefrontal cortices of subjects 
aged 13–79, our group used gene microarray technology to investigate age-related changes in 
gene expression and reported that approximately 7.5% of genes changed significantly with aging 
(Erraji-Benchekroun et al., 2005). Other studies have confirmed these results, identifying a 
maximum of ~10% of all detected genes, depending on sample size and analytical power of the 
respective studies (Glorioso et al., 2011; Yankner et al., 2008). Of note, not only is the identity of 
the genes and gene classes that are affected with aging consistent among studies, but so are the 
directions of change. 
Interestingly, the identity of the genes whose expression changes with age suggests that 
specific cellular populations and biological processes are selectively affected by the aging 
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process. For instance, expression of genes playing a role in glial-mediated inflammation, 
oxidative stress responses, mitochondrial function, synaptic function and plasticity, and calcium 
regulation and neuropeptide signaling have consistently been shown across multiple studies to be 
affected by aging, while numerous other neuronal and glial genes remain apparently unchanged 
(Glorioso and Sibille, 2011; Yankner et al., 2008). Overall, age-upregulated genes are mostly of 
glial origin and related to inflammation and cellular defenses, while downregulated genes display 
mostly neuron-enriched transcripts relating to cellular communication and signaling (Erraji-
Benchekroun et al., 2005). 
Using the expression levels of the age-dependent genes and their expected trajectories 
with age, we have generated predicted ages of individual subjects from which the brain tissue 
was sampled, and demonstrated that this predicted age is highly correlated with the chronological 
age of that individual (Erraji-Benchekroun et al., 2005; Glorioso et al., 2011; Glorioso and 
Sibille, 2011). We have termed this predicted age the “molecular age”. These findings suggest 
that gene expression changes with age can be used as biomarkers for brain aging. 
 
MOLECULAR AGING AND BRAIN-RELATED DISEASE PATHWAYS 
This correlation between molecular and chronological ages is robust in individuals without 
neurodegenerative and neuropsychiatric disorders (Erraji-Benchekroun et al., 2005), but 
investigations of individual genes suggest that the molecular age or individual gene trajectory 
can deviate from chronological age in individuals with these disorders. To illustrate this 
phenomenon, one can look at somatostatin (SST), a signaling neuropeptide that is expressed in a 
subpopulation of gamma-aminobutyric acid (GABA)-positive inhibitory interneurons (Viollet et 
al., 2008). We have demonstrated that expression of SST decreases progressively with age in 
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individuals without neurodegenerative and neuropsychiatric disorders such that expression levels 
at 70 years of age are approximately 40–50% of those at 20 years of age (Erraji-Benchekroun et 
al., 2005; Tripp et al., 2011; Figure 1A). SST is also downregulated in individuals with MDD. 
Interestingly, the magnitude and direction of change in SST expression with age is similar to that 
of control individuals, but the absolute values of SST expression are lower at most ages in 
individuals with MDD compared to those without (Sibille et al., 2011; Tripp et al., 2011; Figure 
1A, top panel). Similar findings have been observed in subjects with schizophrenia (Morris et al., 
2008; Figure 1A, bottom panel). 
 
Figure 22 
 (A) Somatostatin expression decreases with age in control subjects. Individuals with MDD (top panel) and 
schizophrenia (bottom panel) display lower levels of expression than control subjects at most ages, together 
prompting the hypothesis that decreased expression of somatostatin in depression and schizophrenia may represent 
early brain age-related molecular phenotypes in these individuals, which would render these subjects more 
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vulnerable to developing psychiatric diseases. (B) Based on similar age and disease observations for numerous 
additional genes, we have proposed a model of “age-by-disease biological interaction” (Glorioso et al., 2011). In this 
model, change in expression of disease-related genes (a decrease is shown) across a threshold (horizontal blue line) 
marks the onset of disease symptoms. Changes in the trajectory of age-related changes in expression of disease-
related genes (Y-axis) determine at what age (X-axis), or even if, an individual develops disease symptoms (vertical 
red arrows). Modulators (black arrows) may thus place an individual on “at risk” or “protected” trajectory. Per this 
model, individuals with LLD may have modulators, genetic or environmental, that place them on an “at risk” 
trajectory for developing mood symptoms. Figures are adapted from Morris et al. (2008), Tripp et al. (2011), 
Glorioso and Sibille (2011), and McKinney and Sibille (2012). 
The relationship between gene expression of a disorder-associated gene and aging is not 
limited to SST. In fact, genome-wide investigations have reported that up to a third of age-
regulated genes in the human brain have been at some point associated in the literature with 
neurodegenerative (Alzheimer’s, Parkinson’s, and Huntington’s diseases, amyotrophic lateral 
sclerosis) and neuropsychiatric disorders (bipolar depression, major depression, and 
schizophrenia; see Figure 3 in (Glorioso et al., 2011) for details). Not only do the genes relevant 
to these brain disorders show age-related changes, but the direction of the changes that occur 
with age is almost always in the direction thought to cause or promote diseases. See Table 1 in 
Glorioso et al. (2011) for a list of approximately 40 top candidate disease genes that exhibit 
agreement between age- and disease-related changes. Studies of gene expression in Alzheimer’s 
disease (AD) and normal aging find that most of the changes in gene expression that occur in 
normal aging also occur in AD, only in greater magnitude (Avramopoulos et al., 2011; Miller et 
al., 2008). The difference in the magnitude of change in gene expression between individuals 
with brain disease and those without during aging is attributable to the disease. Our hypothesis 
posits that it is these changes that drive the disease process; however, it cannot be ruled out that 
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these additional changes in magnitude are the result of the disease process rather than the cause. 
That said, there are certainly genes for which it is known that the age-related direction of change 
in gene expression directly causes, rather than is a consequence of, the disease, for example, the 
Parkinson’s disease genes PINK1 and DJ1/PARK7. The expression of these genes progressively 
declines with age and it is known that individuals with loss of expression/function mutations in 
these genes develop Parkinson’s disease (Schapira, 2008). In contrast, relatively fewer of the 
larger pool of genes that do not display age-dependent changes (<5%), are associated with 
neurodegenerative and neuropsychiatric diseases. 
Recently, we have further investigated the relationship between age, gene changes, and 
neuropsychiatric disorders, specifically in the context of MDD (Douillard-Guilloux et al., 2013). 
Results demonstrated that most MDD-related genes were frequently age-regulated in both MDD 
and in control subjects, and that the effects of MDD and age were positively correlated. 
Moreover, most genes that are age-dependent in control subjects displayed greater age effects in 
MDD subjects, and the overall increased prevalence of age effects on genes in MDD subjects 
corresponded to similar trends in controls, rather than representing de novo age effects. This 
systematic correlation between age-dependent and depression-related changes, with greater 
effects in depressed subjects, further suggests that normal brain aging is a risk factor for 
biological changes observed in MDD subjects. 
One interpretation of these observations is that age-dependent changes (i.e., molecular 
aging) are on an earlier trajectory in individuals who develop MDD and potentially other 
neuropsychiatric disorders. However, it is important to note that these studies are cross-sectional 
and do not follow the longitudinal progression of gene changes within individuals, so it is not 
known whether age-dependent changes are on an earlier trajectory, or whether changes occurred 
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at earlier time points and were fixed at lower levels, for instance in the case of SST. So while we 
hypothesize that age may be pushing the expression of genes in disorder-causing directions, an 
alternate scenario is that of earlier and fixed changes, which then act as latent vulnerability 
factors that are revealed with advancing age, resulting in increased vulnerability to develop 
neurodegenerative and psychiatric disorders, including LLD. 
 
AGE-RELATED CHANGES IN GENE EXPRESSION APPEAR TO BE, IN PART, 
GENETICALLY MODULATED 
While molecular and chronological ages are highly correlated, we have also reported individual 
deviations from predicted ages (Erraji-Benchekroun et al., 2005; Glorioso et al., 2011). The fact 
that molecular age can deviate from its chronological age suggests that modulating factors exist 
and may contribute to one’s vulnerability to brain aging and to developing late-life brain 
disorders, such as LLD. In the age-by-disease biological interaction hypothesis we have 
proposed that those individuals with older predicted molecular ages compared to their 
chronological age may not only display greater biological brain aging, but may also be at greater 
risk of age-gated brain diseases, because gene expression of disease-related genes would have 
proceeded further in disease-promoting directions. Conversely, subjects with younger age-
dependent gene trajectories and lower predicted molecular ages would be at lower risk, and may 
in fact display resiliency against LLD and other late-life disorders (Figure 1B). Environmental 
and genetic factors represent obvious candidates to modulate the trajectory of biological aging. 
In a proof-of-principle study, our laboratory sought to demonstrate a genetic role in 
modulating the aging process. The above-described “molecular age” assay was used to 
characterize the brain tissue of individuals carrying different polymorphisms of the sirtuin genes 
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(Glorioso et al., 2011), a family of genes previously demonstrated to modulate age and longevity 
in nematodes, insects, and rodents. We focused on SIRT5, due to prior report of altered 
expression for that gene in a rodent model of anticipated brain aging (Sibille et al., 2007). This 
study found that subjects carrying a low-expressing polymorphism of the SIRT5 gene had 
molecular ages that were older than actual chronological age, as measured in the three different 
areas of the cerebral cortex (i.e., BA9, BA24, and BA47) of human postmortem samples 
(Glorioso et al., 2011). Interestingly, this effect was not demonstrated in the amygdala, a brain 
area in which the low-expressing polymorphism of the SIRT5 gene does not appear to affect 
expression levels of SIRT5 as it does in the cerebral cortex. These findings at the molecular level 
are consistent with findings from studies of brain structure with age that show robust decreases 
in gray matter in the cerebral cortex but more variable decreases in the amygdala (Good et al., 
2001). The effect of the low-expressing SIRT5 polymorphism on molecular age was 
accompanied by expression changes for a set of genes whose products are localized to the 
mitochondria, including PINK-1 and DJ-1, two Parkinson’s disease-associated genes, in ways 
that would promote mitochondrial dysfunction-related diseases, including Parkinson’s disease. 
This (correlative) proof-of-principle study suggests that factors that affect brain aging can 
potentially place an individual at higher risk for disease, through a mechanism by which it 
accelerates brain biological aging, and thus promotes changes in expression of disorder-relevant 
genes in disease-causing directions. With respect to Figure 1B, the low-expressing 
polymorphism of the SIRT5 gene can be thought of a modulator that puts one on the “at risk” 
trajectory. The converse of this model is that factors delaying age trajectories of gene changes 
may lead to younger brain molecular aging and potential resiliency toward developing functional 
declines and age-related disorders, including LLD (Figure 1B). 
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PUTATIVE MECHANISMS FOR AGE-RELATED CHANGES IN GENE EXPRESSION 
The mechanisms by which age-related changes in gene expression occur are unknown. 
Candidate mediators include among others, loss of telomere integrity, increased oxidative stress, 
and epigenetic modifications. 
 
Loss of Telomere Integrity 
Telomeres are regions of repetitive nucleotide sequences at each end of a chromosome. One of 
the hypothesized functions of telomeres is to deter the degradation of genes near the ends of 
chromosomes by instead allowing repetitive telomeres to shorten, a necessary part of 
chromosome replication. Telomeres are highly susceptible to oxidative stress because of their 
high content of guanines. As both chromosome replication and oxidative stress increase with age, 
one would expect telomeres to shorten with increased age. Indeed, in peripheral tissues, it has 
been consistently demonstrated that telomeres become shorter as one ages and once telomeres 
reach a critical length, irreversible arrest of cell division or apoptosis is triggered (Chin et al., 
1999; Flores and Blasco, 2009; Hayflick and Moorhead, 1961; Sahin and DePinho, 2012; 
Sharpless and DePinho, 2004). Although telomere shortening has not yet been observed in the 
human brain, studies suggest that peripheral telomere length is a biomarker for aging. Leukocyte 
telomere shortening is positively correlated with the chronicity of stress and depression (Epel et 
al., 2004; Wolkowitz et al., 2011a) and is associated with incidence of age-related diseases such 
as myocardial infarction, stroke, and shorter lifespan (reviewed in (Wolkowitz et al., 2011b). It is 
not known whether telomere shortening increases the risk of LLD, however, given the common 
pathway of aging and depression, the possibility cannot be excluded. 
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Recent animal studies suggest that the putative link between telomere integrity and 
depression-like behaviors extends to the brain, and that this link may be mediated by telomerase 
activity (Zhou et al., 2011). In that study, the expression of telomerase was decreased in the 
hippocampi of mice subjected to chronic mild stress, and hippocampal infusion of a telomerase 
inhibitor induced depressive-like behaviors that did not respond to antidepressant treatment 
(Zhou et al., 2011). Given that neurogenesis has been implicated in antidepressant responses in 
mice (Santarelli et al., 2003) and that the proliferation capacity of neural stem cells highly 
depend on telomerase activity (Ferron et al., 2009), the authors suggested telomerase activity 
may play a role in linking mechanisms of aging and depression (Zhou et al., 2011); although the 
translation of these observations to humans is contentious, due to very low rates of neurogenesis 
in adult human subjects (Bhardwaj et al., 2006). 
The anti-apoptotic role of telomerase is thought to reflect its capacity of maintaining 
DNA integrity, however, recent studies have reported other putative functions (reviewed in 
(Saretzki, 2009). Overexpression of telomerase reverse transcriptase (TERT), protects mouse 
neurons from excitotoxicity by improving basal mitochondrial membrane potential and Ca2+ 
uptake into mitochondria (Kang et al., 2004) and decreases cellular reactive oxygen species 
(ROS; (Ahmed et al., 2008). Furthermore, TERT mediates the neurotrophic action of BDNF (Fu 
et al., 2002) and affects the global pattern of gene expression in the direction of cell survival, 
including upregulation of growth promoting genes (FGF5, EGFR, and etc.) and downregulation 
of cell-growth inhibitors such as IGFBPs (Choi et al., 2008; Smith et al., 2003). Changes in 
telomerase activity with age and MDD have yet to be explored in the human brain. However, 
given the fact that neurotrophic growth signaling, including reduced BDNF, is decreased in 
MDD (Guilloux et al., 2012; Sen et al., 2008; Tripp et al., 2011), we cannot exclude the 
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possibility that telomeres and telomerase activity may significantly contribute to the mediation of 
stress and brain aging. 
 
Increased Oxidative Stress 
Oxidative stress is the damage caused to cells as a result of an imbalance between the production 
of ROS and the ability of the cells to reduce the ROS or repair the resulting damage. The degree 
of oxidative stress to cellular components, including DNA, correlates positively with age (Epel, 
2009; Joseph et al., 2005; Wolkowitz et al., 2011b). Because of their high demand for energy and 
postmitotic status, neurons appear to be particularly sensitive to oxidative stress and thus aging. 
One way in which oxidative stress may contribute to age-related changes in gene 
expression is via its direct effect on DNA. Lu et al. (2004) showed that age-related decrease in 
gene expression is related to the accumulation of oxidative DNA damage. The underlying 
mechanism was suggested that promoter regions with high GC contents are specifically 
vulnerable to oxidative damage. Oxidated promoter regions may potentially adopt different 
conformation and lose affinity for transcription factors (Lu et al., 2004). Damage on 
mitochondrial DNA (mtDNA), which is considered extremely vulnerable to oxidation due to its 
proximity to the site of ROS production, respiratory chain, and the absence of protective histone 
(Lee and Wei, 2007), results in downregulation of genes related to respiratory chain and further, 
energy metabolism impairment (Lin et al., 2002). Several studies showed that psychiatric 
diseases including MDD, bipolar disorder, and schizophrenia are associated with mitochondrial 
dysfunction (Rezin et al., 2009) and that accumulation of mtDNA damage induces mood 
disorder-like phenotypes as well as premature aging in mice (Kasahara et al., 2006; Trifunovic et 
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al., 2004). These results support the idea that oxidative stress plays a role as a link between aging 
and depression. 
Another direct way in which oxidative stress may contribute to age-related changes in 
gene expression is via its effect on transcription factors. For example, ROS are able to activate 
nuclear factor kappa B (NF-κB) by decreasing binding affinity of the inhibitory subunit, Iκ-B, to 
NF-κB, an observation made relevant by the fact that NF-κB activity has been demonstrated to 
increase with aging and depression (Koo et al., 2010; Toliver-Kinsky et al., 1997). Also, 
transcription factors containing the zinc-finger DNA binding motif appear to be especially 
susceptible to damage from oxidative stress due to their high cysteine residue content. As 
intracellular ROS accumulate, oxidation of the thiol residues in cysteine occurs and binding 
affinity for DNA is lost. One of the zinc-finger transcription factors, Sp1, an ubiquitous 
transcription factor for housekeeping genes and enzymes involved in glucose metabolism and 
DNA synthesis, has been demonstrated to have decreased DNA binding affinity with advancing 
age (Ammendola et al., 1992, 1994; Wu et al., 1996). Interestingly, genes with lower affinity 
binding sites to Sp1 are more influenced by oxidative stress than those containing high-affinity 
sites (Ammendola et al., 1992, 1994; Wu et al., 1996). Furthermore, ROS decreases telomerase 
activity. Antioxidant treatment normalizes catalytic activity of TERT and delays cellular 
senescence (Haendeler et al., 2004). 
In addition to the conformational change of gene and transcription factors, ROS can act 
on various cellular signaling pathways to control gene expression. For example, ROS increase 
p53 signaling, which has been implicated in various neurodegenerative diseases and thought to 
mediate its effect by increasing expression of genes related to cell cycle arrest, DNA repair, and 
apoptosis in response to cellular stressors such as DNA damage and hypoxia (Lundberg et al., 
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2000). Another example is illustrated by p38 MAP Kinase (MAPK). When p38 MAPK is 
activated by oxidative stress, it promotes lamin B1 accumulation and expression of several 
transcription factors related to cellular senescence and apoptosis such as p53, CREB, C/EBPβ, 
and ATF2 (Barascu et al., 2012; Wagner and Nebreda, 2009). Interestingly, selective p38 MAPK 
deletion in serotonergic neurons produces stress resilience in an animal model of depression by 
inhibiting serotonin transporter translocation to plasma membrane (Bruchas et al., 2011). 
In summary, the main effect of oxidative stress on aging has been thought to be the 
accumulation of toxic, inactive molecules produced randomly by ROS. However, oxidative 
stress may also have an active role in aging and related diseases, through direct modification of 
DNA and transcription factor integrity and through indirect pathways regulating upstream 
modulators. These observations suggest that antioxidants may contribute to preventing biological 




Epigenetic modifications, including DNA methylation and histone modification, regulate gene 
expression without changing the primary DNA sequence. Though classically viewed as a 
permanent event, recent data indicates that such modifications are influenced by genetic and 
environmental factors in adult organisms, including changes in methylation patterns across the 
lifespan (Numata et al., 2012). At the genome level, DNA methylation decreases with age. In 
contrast, CpG islands of many specific promoter regions that are typically not methylated 
become methylated with aging, including in promoters of tumor suppressor genes, estrogen 
receptor (ER), and insulin-like growth factor 2 (IGF2; (Issa et al., 1994; Issa et al., 1996; Numata 
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et al., 2012; So et al., 2006). Changes in DNA methylation at the glucocorticoid receptor, 
potentially due to early-life stress, was also correlated with altered vulnerability to psychiatric 
disorders and death by suicide in adults (McGowan et al., 2009). 
Similarly, histone modifications such as acetylation, phosphorylation, symoylation, and 
methylation change with age. It was recently demonstrated that the aging-related deficit of long-
term synaptic plasticity in the rodent hippocampus is related to decreased BDNF expression 
secondary to decreased acetylation of histones residing at the BDNF promoter region (Zeng et al., 
2011). This observation fits well with human studies demonstrating reduced BDNF function in 
aging and depression (Guilloux et al., 2012; Webster et al., 2002). Also, changes in histone 
modifications in rodent systems may be protective against the effects of stress (Covington et al., 
2011; Uchida et al., 2011). In support of a specific role for histone acetylation in age-related 
changes in gene expression, sirtuins (NAD-dependent histone deacetylases) have been 
implicated in longevity in yeast and invertebrates (Longo and Kennedy, 2006). A recent rodent 
study directly links SIRT1 to the risk of anxiety-like behaviors through its activity on 
monoamine oxidase A and serotonin levels (Libert et al., 2011). In the same study, the authors 
reported association between a single nucleotide polymorphism in the human SIRT1 gene and 
the risk of various psychiatric disorders such as anxiety disorder, panic disorder, and major 
depression. Furthermore, overexpression of SIRT6 in mice has been reported to increase lifespan 
and protect from diet-induced physiological damage (Kanfi et al., 2012; Kanfi et al., 2010) and 
SIRT6 knockout mice exhibit accelerated aging. Interestingly, decreased expression of SIRT6 
has been observed during MDD (Abe et al., 2011). How SIRT6 mediates its effect on aging or is 
involved in MDD is not clear, but its functions as an HDAC (Kawahara et al., 2009; Michishita 
et al., 2008; Tennen et al., 2011) and in DNA repair (Mao et al., 2011) suggest that it may 
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contribute to protecting against aging and psychiatric illness by maintaining telomere integrity or 
protecting against and repairing the effects of oxidative stress. 
Together, the occurrence of epigenetic modifications during aging and in the context of 
neuropsychiatric disorders may thus provide mechanistic underpinnings for the proposed age-by-
disease biological interaction hypothesis, through the dual role of longevity and other age-
associated genes. 
 
SUMMARY AND IMPLICATIONS 
We propose a novel framework for investigating the development of late-life brain disorders, 
including LLD, which we term the age-by-disease biological interaction hypothesis. This paper 
expands upon an earlier version described elsewhere (McKinney and Sibille, 2013). This 
hypothesis posits that symptoms of LLD and other late-life brain disorders are the emerging 
properties of underlying biological changes, which in turn are supported by normal changes in 
the expression of multiple genes with age, including disease-related genes changing in disease-
causing directions. Here, in addition to presenting the gene expression data on which the 
hypothesis is based, we discussed molecular mechanisms that may account for age-dependent 
gene expression changes, including loss of telomere integrity, increased oxidative stress, and 
epigenetic modifications. Importantly, this hypothesis complements existing hypotheses, 
including the vascular, inflammatory, and dementia prodrome hypotheses of LLD, but it differs 
in that it positions age-dependent gene expression changes as the mechanism potentially driving 
dysfunctions in multiple biological pathways, including vascular, inflammatory, and 
neurotrophic functions. A potential sequence of events is summarized in Figure 2. The purpose 
of this paper was to discuss the general framework. Examples of gene changes at the intersection 
 127 
of depression and aging were provided (e.g., SST and BDNF), but the exact nature and 
complexity of changes in multiple genes and pathways and their relevance to disease pathways 
will be described in details elsewhere. 
 
Figure 23. Proposed sequence of biological events and putative mediators for the age-by-disease biological 
interaction hypothesis. 
From the top: Although its biological substrates are unknown, a chronological clock drives age-related changes in 
gene expression. These changes can be exacerbated by psychophysiological stress and/or genetic variants, and 
placed on accelerated age trajectories. In this model, age-related changes in telomeres, oxidative load and epigenetic 
landscape, among other putative mechanisms, may represent a first level of biological events, which in turn affect 
basic cellular processes involved in regulating gene expression (i.e., including DNA damage, altered structure and 
function of transcription factors (TFs), and associated local cellular signaling). The resulting changes in the global 
pattern of age-dependent gene expression mediate the next set of deleterious biological events, exemplified here by 
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increased inflammation, oxidative damage-related signaling, and changes in neurotransmission. These two levels of 
changes are likely to reciprocally interact. At the neural network and brain levels, the emerging properties of those 
specific cellular events are expressed as senescence in normal aging subjects and, in subjects at risk, as age-related 
symptom dimensions and diseases, including depression. Notably, the degree of individual vulnerability is thought 
to be under genetic and environmental control, so decreased vulnerability may mediate resiliency through the same 
pathways. 
The implications of this hypothesis for the prevention and treatment of LLD and other 
late-life brain disorders are exciting. Understanding the mechanisms mediating age-related 
changes in gene expression is expected to provide insight into pathophysiological mechanisms 
and potential targets for intervention into these disorders. Identifying key upstream hub genes 
mediating patterns of altered age-dependent changes would provide novel targets for further 
investigations. Although sirtuins and BDNF may represent obvious candidates, the large set of 
age-dependent genes (~10% of all genes; (Erraji-Benchekroun et al., 2005)) and its overlap with 
genes previously implicated in brain disorders (Glorioso et al., 2011) should be viewed as an 
enriched pool of candidate genes. Targeting such upstream factors (transcription or function) 
should represent productive research avenues. Early candidate interventions may include known 
interventions such as antidepressant medications, psychotherapy, exercise, and others. 
Investigating how these known interventions affect age-dependent changes in the function of 
critical genes may help in optimizing their implementation with respect to timing and duration of 
intervention for age-dependent disorders. Further, identifying genetic and environmental factors 
that slow or accelerate age-related changes in gene function may lead to individualized strategies 
aimed at promoting resilience and successful aging. Other entry points and targets for 
intervention are likely to arise out of understanding the mechanisms by which gene expression 
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changes with age, including determining the role of telomere integrity, oxidative stress, and 
epigenetic modifications. Finally, for the broader fields of aging and gerontology, the implication 
of this hypothesis is that it brings together research on normal aging more closely with the 
investigation of neuropsychiatric and neurodegenerative diseases. Indeed, our data firmly support 
the assertion that they may in fact be related facets of similar biological processes, and also 
provide the basis for a putative mechanism of age-by-disease biological interactions. 
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Table 5. Demographics of Post-Mortem Subjects 
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Table 6. Cofactor Analysis in Post Mortem Subjects 
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Table 7. Suicide Effect on BDNF and BDNF-Dependent Gene Expression 
Changes in suicide and non-suicide MDD subjects for genes with significant MDD effects are shown below. 
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Figure 24. Full list of GO terms enriched in top 200 genes correlated with BDNF in human frontal cortex as 










Figure 25. Synapse related genes enriched in BDNF coexpression network established with age-residual 
expression values 





Figure 26. Correlation between altered gene expressions measured in array and qPCR 
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Figure 28. UCMS-induced gene expression changes in mouse mPFC 
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Figure 30. SST immunofluorescent signal intensity changes by shRNA treatment 
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Figure 32. Similarity between MDD- and BDNF long 3' UTR knockdown-induced gene expression changes 
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Figure 33. Effect of 7,8-DHF treatment on stress-induced behavior in mice 
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Figure 34. Correlation between TrkB-FL mRNA and protein expression in the mouse brain 
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